Georgia Public Health Laboratory service manual

SECTION I ADMINISTRATION

DHR

Gary B. Redding, Acting Commissioner Kathleen E. Toomey, M.D., M.P.H., Division Director
Elizabeth A. Franko, Dr.P.H., Laboratory Director

Georgia Department of Human Resources $ 2 Peachtree Street, NW $ Atlanta, Georgia 30303-3142 Division of Public Health $ 2 Peachtree Street, NW $ Suite 15-470 $ Atlanta, Georgia 30303-3142 $ (404)
657-2700 Laboratory $ 1749 Clairmont Road $ Decatur, Georgia 30033-4050 $ (404) 327-7900

July, 2001
Dear Public Health Laboratory Customer:
We are pleased to provide you with the July, 2001 revision of the "Laboratory Service Manual" for the Georgia Public Health Laboratory (GPHL). We have retained the ring-binder format and have added a considerable amount of new information about the Central Laboratory Facility in Decatur. We have also included material about additions to our services and changes in the way we provide services. For anyone not aware of it, the Macon Regional Laboratory closed in June, 1999 and those activities have been absorbed by the three GPHL facilities. For those of you who have Internet access, the Laboratory Service Manual is available on the Division of Public Health Web Site at http://www.health.state.ga.us/ under Publications/Manuals & Guidelines/Laboratory Service Manual.
If you ever have any questions about or problems with the services provided by the Public Health Laboratory, please do not hesitate to contact me at 404/327-7900 or to call one of the Supervisors and Mangers listed in the following pages. As always, we solicit your comments and suggestions. Thank you for your continued, enthusiastic support of the Georgia Public Health Laboratory.
Sincerely,
Elizabeth A. Franko, Dr.P.H. Director Public Health Laboratory
AN EQUAL OPPORTUNITY EMPLOYER

I-2

Administrative Office
PH Laboratory Director Elizabeth A. Franko, Dr.P.H. Administrative Operations Manager - George E. Rains PH Laboratory Service Manager Microbiology/Immunology Mahin M. Park, Ph.D. Project Manager Karl E. Hoenes, M.S. PH Laboratory Service Manager Chemistry/Hematology M. Ramachandran, Ph.D.
Program Assistants Kay Felder Audrey Curry
I-3

I-4

I-56 I-5

I-6

GEORGIA PUBLIC HEALTH LABORATORY BRANCHES

Decatur Laboratory:

Georgia Public Health Laboratory CLIA #11D0671793 (Specific Laboratory Unit) 1749 Clairmont Road Decatur, GA 30033-4050

Individual Units and Telephone Numbers:

Unit

Telephone

Administrative

(404) 327-7900

Office

FAX (404) 327-7919

Bacteriology

(404) 327-7990

Central Accessioning

(404) 321-2281

Laboratory Supply

(404) 327-7920

LIS Office

(404) 327-7931

Microbial Immunology

(404) 327-7970

Mycobacteriology

(404) 327-7940

Mycology

(404) 321-2260

Newborn Screening

(404) 327-7950

Parasitology

(404) 327-7960

Reports and Records

(404) 321-2240

Virology

(404) 327-7980

Regional Public Health Laboratories: Albany Regional Laboratory CLIA #11D0671770 1109 N. Jackson Street Albany, GA. 31701-2022 (229) 430-4122 FAX (229) 430-5143
Waycross Regional Laboratory CLIA #11D0671837 1101 Church Street Waycross, GA. 31501-3525 (912) 285-6000 FAX (912) 285-6032

Specimen Collection outfits: Order outfits from the Laboratory Branch, which will perform the test (see below). Mailing labels are pre-addressed to the branch providing the outfits.

Georgia Public Health Laboratory Laboratory Supply 1749 Clairmont Road Decatur, GA 30033-4050 (404) 327-7920

Albany Regional Laboratory 1109 N. Jackson Street Albany, GA 31701-2022 (229) 430-4122

Waycross Regional Laboratory 1101 Church Street Waycross, Ga. 31501-3525 (912) 285-6000

Procedure for Payment of Tests: Tests are paid for by a pre-paid stamp system. Stamps may be purchased, in the amounts of $1.00, $4.00, and $8.00 from the Georgia Public Health Laboratory, 1749 Clairmont Road, Decatur, GA. 30033-4050, (404) 327-7900. See Fee Code column of the List of Services, Section VII, for charges for specific tests.

I-7

I-8

SECTION II OPERATIONS

TRANSPORTATION
There have been recent changes in the United States Postal Service (USPS) guidelines for shipping hazardous materials through the mail. The Georgia Public Health Laboratory is in the process of revising our shipping outfits for infectious substances (etiological agents) so they will be in compliance with these new regulations. We have been advised by our local postal representative to use the current outfits specified in each of the technical sections of this manual until we are in a position to provide new ones. We will be informing our clients of the availability of these new outfits in the near future. Packages delivered by courier or other carriers are subject to the guidelines of the specific company.
The information below defines the difference between infectious substances and clinical specimens. Also provided below is a summary of the shipping guidelines for each of these categories, which have been taken from Publication 52, July 1999, Hazardous, Restricted, and Perishable Mail, and the Federal Register 49 CFR Part 72. In general, the USPS has adopted the regulations specified by the International Air Transport Association (IATA). Appendix A of this manual gives further detailed USPS guidelines on the transport of infectious substances/etiological agents and diagnostic specimens, as well as Federal Express guidelines and the IATA standards.
Infectious substances (etiological agents) are substances known to contain, or reasonably expected to contain, a pathogen(s), i.e. a viable microorganism, or its toxin, that causes or may cause disease in human beings or animals. Infectious substances are synonymous with "etiologic agents." Table 1 lists the bacterial, fungal, viral and rickettsial agents that are "etiologic agents," according to 42 CFR Part 72.3. Clinical specimens (diagnostic specimens) mean any human or animal material including, but not limited to, excreta, secreta, blood, blood components, tissue, and tissue fluids that have been collected and are being mailed to a medical or forensic laboratory for the purpose of diagnosis. These substances are not known, or not reasonably believed to contain, an infectious substance.
Packages containing infectious substances that are to be transported by the USPS are subject to the following standards:
Each mailpiece should contain no more than 50 ml of infectious substance(s). Infectious substances must be packaged in a sealed, waterproof, primary receptacle
(test tube, vial, etc.) that is enclosed in another securely sealed, watertight, and durable secondary packaging. Several primary receptacles may be enclosed in a single secondary packaging if there is adequate shock-absorbent material between them to prevent breakage during ordinary handling, and if the total liquid volume of all enclosed primary receptacles does not exceed 50 ml. The space between the primary receptable(s) and secondary packaging at the top, bottom, and sides must contain enough material to absorb the entire content of the primary receptacle(s) in case of breakage or leakage. The primary-receptacle(s) and secondary packaging must be placed in a sealed outer packaging constructed of fibreboard or other equivalent material.
II-1

A return address must be included on the outside of the package. Each outer packaging that contains infectious substances must bear: the "Etiologic
Agent/Biohazard Material" label, the DOT Class 6 label for infectious substances, the proper shipping name and UN number ("Infectious Substances Affecting Animals," UN2900, or "Infectious Substances Affecting Humans," UN2814), and orientation markings that properly indicate the upright position of the primary receptacle(s). A shipper's declaration for dangerous goods is required. The package must be sent by Express Mail, Priority Mail, or First-Class Mail. Specific infectious substances must be sent registered mail (see Table 2). When dry ice is used as a refrigerant, it must be placed outside the secondary container, and never be placed in a sealed container. If it is placed between the secondary container and the outer shipping container, enough shock-absorbent material must be added so that the secondary container does not become loose as the dry ice sublimates. A class 9 label should be applied to the outside container.
The packaging of clinical or diagnostic specimens that are to be transported by USPS must meet the following guidelines:
A clinical specimen consisting of 50 ml or less per mailpiece must be packaged in a securely sealed primary receptacle. Sufficient shock-resistant, absorbent material must surround the primary receptacle, or be otherwise configured to take up the content in case of leakage. The primary receptacle and the absorbent cushioning must be enclosed in a secondary packaging having a leakproof barrier. The secondary packaging may serve as the outer packaging or may be placed in an outer container.
Clinical specimens that exceed 50 ml per mailpiece must meet the above guidelines, but the secondary packaging must be placed in an outer fibreboard box or equivalent container. Each primary receptacle must not contain more than 1,000 ml of specimen, and the combined volume must not exceed 4,000 per mailpiece.
Each mailpiece must be marked "Clinical Specimen, Blood Sample," "Clinical Specimen, Urine Sample," etc., as appropriate, and must bear the universal biohazard symbol.
A complete return address and delivery address must be used. When dry ice is used as a refrigerant, it must be placed outside the secondary
container, and never be placed in a sealed container. If it is placed between the secondary container and the outer shipping container, enough shock-absorbent material must be added so that the secondary container does not become loose as the dry ice sublimates. A class 9 label should be applied to the outside container.

NOTE:

Blood specimens collected on filter paper (Form #3491) for the Newborn

Screening laboratory should continue to be mailed in the envelopes provided.

In the event of damaged packages, the carrier shall promptly, upon discovery of evidence of leakage or any other damage to packages bearing the Etiologic Agents label, isolate the package and notify the Director, Centers for Disease Control and Prevention, 1600 Clifton Road, N.E., Atlanta Ga. 30333, by telephone (404) 633-5313. The carrier shall also notify the sender.

II-2

Table 1. List of "Etiologic Agents," from 42 CFR Part 72.3

Acinetobacter calcoaceticus- all members Actinobacillus all members

Bacterial Agents Leptospira interrogans all serovars Listeria all species

Actinomycetaceae all members Aeromonas hydrophilia Arachnia propionica

Mima polymorpha Moraxella all species Mycobacterium all species

Arizona hinshawii all serotypes Bacillus anthracis Bacteroides spp.

Mycoplasma all species Neisseria gonorrhoeae, N. meningitidis Nocardia asteroides

Bartonella all species Bordetella all species Borrelia recurrentis, B. vincenti

Pasteurella all species Plesiomonas shigelloides Proteus all species

Brucella all species Campylobacter fetus, C. jejuni Chlamydia psittaci, C. trachomatis

Pseudomonas mallei Pseudomonas pseudomallei Salmonella all species and all serotypes

Clostridium botulinum, C. chauvoei, C. haemolyticum, C. histolyticum, C. novyi, C. septicum, C. tetani

Shigella all species and all serotypes Sphaerophorus necrophorus Staphylococcus aureus

Corynebacterium diptheriae, C. equi, C. haemolyticum, C. pseudotuberculosis, C. pyogenes, C. renale

Streptobacillus moniliformis Streptococcus pneumoniae Streptotoccus pyogenes

Edwarsiella tarda Erysipelothrix insidiosa Escherichia coli, all enteropathogenic serotypes

Treponema careteum, T. pallidum, and T. pertenue Vibrio cholerae, V. parahaemolyticus

Francisella tularensis Haemophilus ducreyi, H. influenzae Klebsiella all species and all serotypes

Yersinia (Pasteurella) pestis, Y. enterocolitica

Legionella all species and all Legionella-like organisms

Blastomyces dermatitidis Coccidioides immitis Cryptococcus neoformans

Fungal Agents Histoplasma capsulatum Paracoccidioides brasiliensis

Viral and Rickettsial Agents

Adenoviruses human all types

Infectious bronchitis-like virus

Arboviruses all types

Influenza viruses all types

Coxiella burnetii

Kuru agent

Coxsackie A and B viruses all types

Lassa virus

Creutzfeldt-Jacob agent

Lymphocytic choriomeningitis virus

Cytomegaloviruses

Marburg virus

Dengue viruses all types

Measles virus

Ebola viruses

Mumps virus

Echoviruses all types

Parainfluenza viruses all types

Encephalomyocarditis virus

Polioviruses

Hemorrhagic fever agents including, but not limited to,

Rabies virus all strains

Crimean hemorrhagic fever(Congo), Junin, Machupo viruses, Reoviruses all types

And Korean hemorrhagic fever viruses

Respiratory syncytial virus

Hepatitis associated materials (Hepatitis A,

Rhinoviruses all types

Hepatitis B, Hepatitis nonA-nonB)

Rickettsia all types

Herpesvirus all members

Rochalimaeae quintana

II-3

Table 1 (continued) List of "Etiologic Agents," from 42 CFR Part 72.3

Viruses and Rickettsial Agents (continued)

Rotaviruses all types

Vaccinia virus

Rubella virus

Varicella virus

Simian virus 40

Variola major and Variola minor viruses

Tick-borne encephalitis virus comples,

Vesicular stomatis viruses all types

including Russian spring-summer encephalitis, Kyasanur forest disease,

White pox viruses Yellow fever virus1

Omsk hemorrhagic fever, and Central

European encephalitis viruses

1This list may be revised from time to time by Notice published in the Federal Register to identify additional agents which must be packaged in accordance with the requirements contained in this part.

Table 2. List of Infectious Substances Requiring Registered Mail/Receipt Notification during Transport (42 CFR Part 72.3)
Coccidioides immitis Ebola virus Francisella ( Pasteurella) tularensis Hemorrhagic fever agents including, but not limited to, Crimean hemorrhagic fever (Congo), Junin, Machupo viruses, and Korean hemorrhagic fever viruses Herpesvirus simiae (B virus) Histoplasma capsulatum Lassa virus Marburg virus Pseudomonas mallei Pseudomonas pseudomallei Tick-borne encephalitis virus complex including, but not limited to, Russian spring-summer encephalitis, Kyasanur Forest disease, Omsk hemorrhagic fever, and Central European encephalitis viruses Variola major, Variola minor, and whitepox viruses Yersinia (Pasteurella) pestis

II-4

SUPPORT SERVICES
II-5

II-6

LABORATORY SUPPORT SERVICES INTRODUCTION
All non-technical laboratory responsibilities are performed by several specialized units which comprise the Laboratory Support Services Unit. This Unit is supervised and administratively represented by the Administrative Operations Manager.
Well organized, support services have always been a vital part of any efficiently functioning operation. Electronic data processing, has expanded the role of Support Services in the Laboratory Branch. The Central Accessioning area was added in 1999. Also in 1999, the Office of Laboratory Information Systems was removed from the Support Service Unit.
Components of the Georgia Public Health Laboratory Support Services Unit and a brief statement of responsibilities are listed below:
(a) Central Accessioning All specimens sent to the Public Health Laboratory for testing are processed through the Central Accessioning area. Here the specimens are opened, numbered and entered, electronically, into the Laboratory Information System (LIS).
(b) Reports and Records Office This office processes laboratory result reports Electronically, by U.S. Mail and Courier Services. Copies of reports are kept on file for reference, and record retention schedules are coordinated with DHR through this office.
(c) Service and Supply Unit This unit provides all technical and non-technical purchasing services for the Laboratory. All equipment Maintenance Contracts and in-house maintenance service are provided from this unit. The Procurement and Services Officer for this unit participates in and monitors the budget process for regular operating expenses.
(d) Scientific Services Unit This Unit handles the preparation of specialized media as requested from any of the technical areas. This unit also handles sterilization and biohazardous waste disposal.
(e) Laboratory Fee System This unit handles the sale of Laboratory fee stamps and processes the proceeds from the sale.
II-7

The Support Service Unit clients consist of the general public and co-workers within the Laboratory Branch. It is our goal to provide the best services possible so that working together, we can provide efficient Clinical Laboratory services to the citizens of Georgia. George Rains, Administrative Operations Manager
II-8

Services & Supply Unit

Unit Personnel

Receiving Area

Specimen Outfit Area

Program Assistant - Maxine Simpson
Procurement & Services Officer Regenia McCord

II-9

II-10

LABORATORY SERVICES AND SUPPLY UNIT The Laboratory Services and Supply Unit operates with a staff of eight. This unit provides support services, in the areas listed below, to the Decatur, Albany and Waycross Public Health Laboratories. Additionally, employees in this Unit assemble and distribute specimen submission outfits to clients of the Decatur Laboratory (see page II-13). PURCHASING: The Procurement and Services Officer, who manages this unit is responsible for purchasing all laboratory testing materials and reagents used in the three Public Health Laboratories. These purchases are accomplished with appropriated funds and by adhering to strict purchasing guidelines imposed by the Department of Human Resources and the Department of Administrative Services. It is also the responsibility of this unit to administer grant funds covering regular operating expense for special projects in which the laboratory participates. EQUIPMENT MAINTENANCE: Approximately twenty-five equipment maintenance contracts are negotiated annually to ensure rapid and competent service for technical lab equipment. These contracts and other building maintenance needs are handled by a Maintenance Coordinator who is a member of the Service & Supply staff. MAIL HANDLING: All incoming and outgoing mail is processed through the Service & Supply Unit. US Mail is sorted and delivered to the appropriate areas. SHIPPING AND RECEIVING: All deliveries for the Decatur Laboratory are received and signed for in the Service and Supply area. Outgoing shipments are also processed through this area. COURIER SERVICE: Courier service is provided for the Decatur facility through the Service and Supply unit.
II-11

II-12

SPECIMEN COLLECTION OUTFIT ODERING INFORMATION

Specimen collection and transportation supplies are provided COST-FREE by the GA Public Health Laboratories in Decatur, Albany, and Waycross. Supplies are provided only for specimens submitted to Georgia Public Health Laboratories. Supplies are not provided for submitting specimens to other testing laboratories.

Supplies are to be ordered from the laboratory location where the specimen will be sent for testing. Refer to section VII, pages 1-34 in the List of Services Section to determine the laboratory location where a particular test is available, the correct outfit name, and the item number to order. Specimens submitted incorrectly must be forwarded to the appropriate test site, and this delays the turnaround time.

TO ORDER SUPPLIES: Complete a Specimen Collection Outfit Order Form for the appropriate laboratory location (see Appendix B, pages 3-8 for specific examples). Each laboratory's order form lists only the supplies available at that location. Order only the supplies needed, as collection outfits have expiration dates. Supplies are available as:
(1) Outfits, which include the submission form, instructions for collecting and transporting specimens, the collection container, specimen bags, and a pre-addressed mailing container;
(2) Individual items, if only single items are needed; and (3) Forms, if only individual submission forms are needed. Order quantities by "the each;" do not order by the box unless noted on the order form. See Appendix C for the specific components of each type outfit. Provide the full street address as orders are shipped by UPS. If only the P.O. Box is given, the order cannot be shipped. Include the name and telephone number of the person ordering.

For those clients with Internet access, many of the GPHL submission forms are also available on the Division of Public Health Web Site at http://www.gdph.state.ga.us under Publications/Manuals & Guidelines/Laboratory Service Manual/Forms. As new forms are updated, these will be added.

For additional ordering information, please contact:

Decatur

Regenia McCord (404) 327-7921

Albany

Ann Blalock

(229) 430-4122

Waycross Frances Bowen

(912) 285-6000

II-13

II-14

Central Accessioning/Data Processing Unit
Central Accessioning Personnel
Data Processing Personnel
Associate - Jenuryl Fluellen Technician - Greg Simpson Data Transcriber Supervisor Juanita Johnson
II-15

II-16

CENTRAL ACCESSIONING / DATA ENTRY UNIT

The Accessioning Unit is the entry point for all specimens submitted for testing to the Central Public Health Laboratory in Decatur or one of the branch laboratories in Albany or Waycross.

The Decatur Unit is divided into two areas. The first area is where the specimens are opened, sorted and assigned a number. All specimens are processed on the day received and delivered to the testing laboratory. All specimens must have a submission form indicating the test requested. Central Accessioning ensures that a name or unique identifier is on the specimen and that the name and unique identifier matches the name and unique identifier on the submission form. If either of these conditions are not met, the specimen is not delivered to the testing laboratory, and a report of "unsatisfactory" is sent to the Client.

The second area, Data Entry is where the submission information for each specimen is electronically entered into the Laboratory Information System (LIS). The data entry area ensures that patient demographics and test requested are entered in an accurate and timely manner.

The two branch laboratories have the accessioning area arranged to meet their specific needs.

For information concerning the receipt of specimens or accessioning information, contact:

Jenuryl Fluellen Ann Blalock Frances Bowen

Decatur Lab Albany Lab Waycross Lab

404/321-2281 229/430-4122 912/285-6000

II-17

II-18

Reports & Records Unit
Unit Personnel
Office Manager Shirley Simmons-Walton Program Assistant Lavette Usher
II-19

II-20

REPORTS AND RECORDS UNIT

Reports and Records Units in the Public Health Laboratories in Decatur, Albany and Waycross perform three (3) essential functions:

1. Report laboratory findings. 2. Maintain records and statistical data. 3. Serve as a liaison/communication network with clinicians, public health officials and the
general public.

The Reports and Records Units in the Albany and Waycross Regional Laboratories report laboratory findings for the tests performed at the respective locations.

The Reports and Records Unit in the Decatur Laboratory reports laboratory findings for the majority of the tests performed at this location, with a few exceptions noted below. To make telephone inquiries about the status of a particular specimen, contact Reports and Records (404) 321-2240 or the appropriate section. Please note: Information can only be provided to the treating clinician, not to the patient.

Bacteriology

Reports and Records reports all testing. Contact Reports and Records for report status.

Microbial Immunology

Reports and Records reports all testing. Contact Reports and Records for report status.

Mycobacteriology/ Mycology Newborn Screening
Parasitology
Virology

Reports and Records reports all testing. Contact Reports and Records for report status.
Reporting is provided by Reports and Records. Contact Newborn Screening for report status and duplicate reports
at (404) 327-7950.
Reports and Records reports all testing. Contact Reports and Records for report status.
Reports and Records reports most testing. Exception: Rabies, contact the Laboratory at (404) 327-7980.

II-21

Reports are provided only to the submitting clinician (the doctor submitting the specimen for testing). Currently, these reports are provided in one of three formats:
A. A machine copy of the submission form onto which laboratory findings are recorded.
B. Submission form on which laboratory findings are recorded in selected cases.
C. A computer-generated report form containing the laboratory findings and pertinent information provided on the submission form.

Laboratory test records are retained by Reports and Records for a year after reporting. Records are then forwarded to the State Records Center where they are retained for an additional year before destruction. Duplicate copies of laboratory test reports, can be provided upon request from the original submitting clinician. Proper identification is essential. All requests for more than five reports must be submitted in writing.
For additional information on Reports and Records, please contact:

Decatur Shirley Simmons-Walton

Albany

Ann Blalock

Waycross Frances Bowen

404-321-2241 229-430-4122 912-285-6000

II-22

Scientific Services Unit

Unit Personnel

Media Preparation

Sterilization and Waste Disposal

Fluoride Testing
II-23

II-24

SCIENTIFIC SERVICES UNIT The Scientific Services area prepares microbiological culture media for the Decatur Laboratory and two diagnostic regional laboratories located in Albany, Georgia and Waycross, Georgia. Media is also prepared for the Newborn Screening area of the Decatur facility. All newborns in the state of Georgia are screened for 8 metabolic disorders using media prepared in this area. Sterilization and biohazardous waste disposal for the entire Decatur facility are handled through the Scientific Services area. Glassware is also cleaned, sterilized and delivered to the labs. January 1, 2000, the Scientific Services Unit began fluoride proficiency testing for the DHR, Office of Oral Health. Each water system, in Georgia, that adjusts the fluoride level in drinking water is asked to participate in this proficiency testing. This work had previously been handled by the Environmental Protection Division of the Georgia Department of Natural Resources. If you have questions or wish further information on Scientific Services/Media Preparation you may call one of the people listed below:
George Sweeney, Scientific Services Manager, phone 404/327-7967 Michael Colbert, Laboratory Technologist, phone 404/327-7966
II-25

II-26

Laboratory Information System
Laboratory Information Coordinator - Shane Crockett LAN Engineer - Marv Coleman
II-27

II-28

LABORATORY INFORMATION SYSTEMS UNIT
The Laboratory Information Systems Unit provides a support function for all of the information and data system needs of the GPHL. The Laboratory Information Systems (LIS) are key elements of the laboratory for maintenance of precise records on all specimens that are handled by the laboratory. Not only are data captured identifying the specimen, requestor, and tests to be performed, but many items that assist the Public Health programs in the delivery, assessment and management of their services. The Unit is staffed to cover the two major areas of responsibility. The first is the support, development and maintenance of the LIS. This responsibility involves the integration of the technical aspects of the laboratory operation with the computer-based software systems that collect, display and report the tests performed on specimens. The data analysis and information transfer requirements of the laboratory are met in this responsibility. Responsibility is staffed with personnel of the laboratory. The second responsibility concerns the installation, maintenance and enhancement of the physical computer assets that are required to support the operation of the LIS. The LIS employ the latest technologies in the LANs, servers and interfaces to the automated specimen testing systems. Support is provided for a LIS that operates in three separate locations that must operate concurrently yet function separately in certain emergency situations. This responsibility is staffed by personnel from the IT Unit of the Department of Human Resources.
II-29

II-30

Laboratory Training Area
Training Classroom
Training Laboratory Library/Conference Room
II-31

II-32

LABORATORY TRAINING The GPHL in Decatur houses a training facility consisting of a laboratory, classroom, and satellite downlink equipment for the purpose of providing training opportunities for public health staff in Georgia. The classroom can seat 24 in a classroom configuration and more than 40 for lectures. The training laboratory is a sixteen place BioSafety Level 2 (BSL2) space with two attached BSL3 suites. Each BSL3 suite contains an incubator and two biosafety cabinets. There is a fume hood in the specimen preparation area. The GPHL is a member of the National Laboratory Training Network (NTLN) and participates in a number of training program offered by the NTLN. The GPHL hosts training programs organized and administered by the NTLN in a variety of public health subject areas. The GPHL satellite downlink equipment connects the Laboratory with the wide range of training programs offered by the CDC through the Public Health Training Network as well as the health departments of other states.
II-33

II-34

SECTION III BIOTERRORISM

BIOTERRORISM
They say it's not a question of "if" but rather "when" we will have a bioterrorism attack. We may find it hard to believe that a biological attack could occur here, but it is well documented by agencies with expertise in weapons of mass destruction (WMD), that the United States is vulnerable to the deliberate use of biological agents. Homeland defense is no longer the responsibility of only the military and law enforcement infrastructure. Clinical laboratories have an important role to play.
Background: In order to address the threat of bioterrorism (BT), CDC and the Association of Public Health Laboratories (APHL) have established the "Laboratory Response Network" (LRN). The LRN includes all state public health laboratories as well as CDC, the FBI Laboratory and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) as well as other clinical labs. The concept of the LRN is based on strengthening existing state, local and federal public health laboratories and improving linkage with the network of private and hospital laboratories that submit specimens for routine and referral testing to the public health system. The Georgia Public Health Laboratory (GPHL) is an active member of the LRN, participating in development of consensus protocols for testing for BT agents, training, and infrastructure improvement. Because bioterrorism events are low probability, high consequence events, the capabilities for bioterrorism have functionality beyond emergency response, and are applied to surveillance and identification of the causes of infectious disease outbreaks.
To ensure capacity and responsiveness, a four-tier LRN model has been defined. This model describes a laboratory network that can detect, identify and communicate timely information concerning the occurrence of an infectious disease or bioterrorism event to aid in effective interventions to treat cases and prevent the spread of disease. The LRN consist of:
v Level A: Any clinical laboratory that can rule out specific/critical agents and forward specimens to a higher level laboratory. By rule-out or referral, these laboratories provide early detection. They should assess for risk from aerosols and work at a minimum of biosafety level 2 (BSL-2) capacity.
v Level B: Any state and/or county public health laboratory that can rule-in specific/critical agents, forward specimens to higher level laboratories, process environmental samples, perform confirmatory testing and antibiotic susceptibility testing. These laboratories are usually BSL-2 working with BSL-3 practices (recommended).
v Level C: State public health laboratories with advanced capacity, nucleic acid amplification assays, antigen detection assays, molecular typing, and ability for surge capacity. These laboratories work at BSL-3.
v Level D: These laboratories include the CDC and USAMRIID facilities. They are able to perform all A to C tests, validate new assays, detect genetic recombinants, provide
III-1

specialized reagents, bank/archive isolates, perform molecular typing and test for smallpox. They can perform work to the highest, BSL-4, capacity.
Bioterrorism attacks are expected to be either overt (announced) or covert, perhaps affecting a large number of people at a public gathering. In covert attacks, as victims seek medical intervention, illness may be reported in random locations for some time after the initial exposure. Primary health care facilities such as hospitals, primary care physicians, and county health departments may be the first to deal with the consequences of a covert attack. Health care providers should be able to:
v Recognize the possibility of a bioterrorist attack. v Be prepared to act quickly v Have contact name and telephone numbers readily available. v Develop a bioterrorism preparedness plan. v Presumptively identify bioterrorism organisms. v Send suspected organisms to the nearest public health laboratory for confirmation. v Report notifiable diseases to State Office of Epidemiology.
By improving communications within the health care system, a more efficient, effective means of detecting and responding to biological emergencies can be achieved. Improving the public health infrastructure not only helps with timely response to a bioterrorist event, but also enhances the existing mechanisms for the early detection of an emerging infectious disease. Basic laboratory information for Level A Laboratories is available for public access at www.bt.cdc.gov.
GPHL Capacity: The GPHL Central Facility in Decatur has biosafety level 3 (BSL-3) capability for the isolation and identification of bioagents in the event of bioterrorist attack. The laboratory has the capacity to identify the organisms believed most likely to be used in a bioterrorist attack. Currently, these include Bacillus anthracis (Anthrax), Francisella tularensis (Tularemia), Yersinia pestis (Plague), and Brucella species (Brucellosis). Specimens for Variola major (Smallpox) and Clostridium botulinum toxin are sent to CDC for testing. Additional infectious organisms and toxins will be added to the BT profile of agents in the future, as consensus protocols are developed.
Submission of Specimens: The GPHL will accept specimens from the two possible types of events. Environmental (overt) specimens (threat letters, notes, papers, envelopes, powder, etc.) should be double bagged and handed over to law enforcement (FBI) for delivery to the GPHL. Because a terrorist attack, or even the threat of such an action, is a federal offense, it is critical that appropriate chain of custody be established to preserve the integrity of potential evidence.
Reference specimens (possible covert event) should be submitted to the GPHL from any hospital or other clinical laboratory in the state. If bioterrorism is suspected, it is important to contact law enforcement (FBI). A "Culture Referral/Isolation for ID" (form #3410) should accompany the specimen. Please refer to the Bacteriology or Virology sections of this manual for other specific information.
III-2

Important Telephone Contacts: Local Police : ____________________________________________ Local Fire Department : ___________________________________ Local EMS: _____________________________________________ Federal Bureau of Investigation (FBI): 404-679-9000 (Atlanta)
Local FBI office: _______________________________ Georgia Poison Control Center (24/7 coverage):
404-616-9000 (metro Atlanta) 1-800-282-5846 (throughout Georgia) 404-616-9287 (for hearing impaired only Teletype TTY) Georgia Public Health Laboratory (business hours): 404-327-7900 (Main phone) 404-327-7990 (Bacteriology Unit) 404-327-7980 (Virology Unit)
III-3

III-4

SECTION IV
CENTRAL FACILITY (DECATUR)

CHEMISTRY/HEMATOLOGY/METABOLIC SCREENING SERVICES INTRODUCTION
Newborn screening is offered free of charge to Georgia residents as mandated by Georgia Law. All newborns are screened for possible incidence of phenylketonuria (PKU), tyrosinemia, homocystinuria, maple syrup urine disease (MSUD), galactosemia, hypothyroidism, congenital adrenal hyperplasia and Sickle Cell Disease. This manual describes the overall policies and procedures of laboratory testing by the State Public Health Laboratories that includes Newborn Screening. Specific instructions for specimen collection, preparation of appropriate requisition forms and guidelines for proper packaging and transport of specimens are outlined under relevant headings. Details regarding procurement of collection outfits, specimen acceptance policies, turn-around time for different tests, reporting results and interpretation are also given. Testing procedures and other exclusive services (like the blood lead) performed at each of the Regional Laboratories and at the laboratory in Atlanta are described independently. It is hoped that this manual will serve as a resource guide for submitters for all the information that they may need in looking for a particular test and getting it done by any of the State Public Health Laboratories. The relevant contact persons and their telephone numbers are provided. The submitters are encouraged to use them freely before they initiate a test request. M. Ramachandran, Ph.D. Laboratory Clinical Program Director Chemistry/Hematology/Metabolic Screening Services
IV- 1

IV- 2

Newborn Screening Unit

Unit Personnel

Associate - Henry Carson, B.S. Manager - Sandra Hollman, B.S.

Data Transcriber II - Emma Martin Data Transcriber Supervisor - Michelle Dukes Program Assistant - Sondra Rates
IV- 3

IV- 4

NEWBORN SCREENING UNIT 404-327-6800

INTRODUCTION

The Newborn Screening Unit fulfills a Georgia mandate that requires that all infants born in the state are tested, before the first month of life, for certain inherited metabolic disorders that may cause mental retardation or death if not detected within this time frame. The Genetics Division of the Department of Pediatrics at Emory University School of Medicine provides all the followup work on positive infants (confirmation, counseling, treatment, etc.) with metabolic disorders. Universal Screening for Sickle Cell Disease was introduced by the State in October 1998 and is performed at the Laboratory in Atlanta. All testing is done on blood specimens collected on filter paper. Present protocol includes testing for specific compounds/metabolites in blood as indicated.

PHENYLKETONURIA (PKU): Phenylalanine is measured

HOMOCYSTINURIA:

Methionine is measured

MAPLE SYRUP URINE DISEASE (MSUD):

Leucine is measured

TYROSINEMIA:

Tyrosine is measured

GALACTOSEMIA:

Uridyl transferase qualitatively assayed on all specimens. Galactose and galactose-1-phosphate, quantitatively measured on all positives and inconclusives.

HYPOTHYROIDISM:

Thyroxine (T4) is measured on all specimens. Thyroid stimulating hormone (TSH) is measured on a selective lowest percentile of T4 values.

CONGENITAL ADRENAL HYPERPLASIA (CAH):

17-OH-Progesterone is measured.

SICKLE CELL DISEASE:

Screening is done by Isoelectric focussing. Presumptive positives are confirmed by HPLC and Citrate agar electrophoresis.

SPECIMEN COLLECTION/LABELING/REQUISITION FORM
Excerpts from "BLOOD COLLECTION ON FILTER PAPER FOR NEONATAL SCREENING PROGRAMS", NCCLS Document LA4-A, Vol. 8 No. 9
IV- 5

A. MATERIALS NEEDED 1. Form 3491 is the combination collection outfit and patient information instrument. A pre-addressed envelope is also available. Order these from: Laboratory Services and Supply, 1749 Clairmont Road, Decatur, GA 30033, (phone: 404-327-7921). Ask for form #3491 for Metabolic screens and #3603 for the pre-addressed envelope. Order sufficient amounts that can be used within six months. Store in a cool dry area. When submitting metabolic screens to our laboratory, use only the material we supply. These filter paper collection outfits are to be used prior to the expiration date, which is approximately two years from the printing date. The expiration date is on the filter paper portion. Destroy all outfits after the expiration date. The forms currently in use include a protective wrap-around cover for the filter paper, and do not require an individual envelope for each specimen card. 2. 75% isopropanol 3. Sterile lancets with a point of 2.5 mm in length. A LONGER POINT MIGHT PIERCE THE HEEL BONE. Sterile prepackaged lancets designed for pediatric use are available through private vendors. 4. Sterile gauze 5. Gloves
B. Recommendations for Blood Collection 1. Normal Infants - The infants should preferably be on a protein diet 24 hours prior to collecting the blood sample. The sample should be collected between 48 hours and 7 days of birth. 2. Early Discharge of a Normal Infant - If the infant is discharged earlier than 48 hours after birth, or before a 24 hour period of protein feeding, a specimen should still be collected. Write on the report form the infant's age at the time the blood was collected. The parents are to be informed in writing that the child must be retested by one week of age. 3. Sick Babies - Collect a blood sample on the fourth day of life. Note on the report form if the infant is being given specific therapy,i.e. antibiotics, hyperalimentation, etc. The blood sample should again be collected by one week of age. 4. Premature Infants - Infants less than 36 weeks gestation or 5 1/2 pounds or less in weight at birth should be retested when the child is about four weeks of age. Collect the first specimen 24 hours after protein feeding or 48 hours after birth. 5. How Much Blood To Collect - Six(6) spots of blood should be submitted in order to provide sufficient blood if retesting is required. If the infant is not bleeding freely, for initial screening purposes, three spots completely filled are better than five spots incompletely filled. 6. Interference: Antibiotics and Transfusions - Some antibiotics interfere with the testing for PKU, MSUD, homocystinuria, and tyrosinemia. When this occurs the results will be reported as "Unsatisfactory-Bioassay Inhibited". If the infant is to be transfused, collect a specimen before the transfusion regardless of the age. If the child is less than 48 hours old, collect a second sample one week after the last transfusion and a third sample two months after the last transfusion.
IV- 6

C. Collection Procedure 1. HEEL STICK ABSORPTION (METHOD OF CHOICE) a. The blood collector should wear gloves and take universal precautions for handling blood. b. Collect the blood from the infant's heel, using the most medial or lateral portion of the plantar surface of the heel, where "medial" is defined as that close to the midline of the body, and "plantar surface" as the walking surface of the foot. DO NOT use previous puncture sites or the curvature of the heel. DO NOT perform skin punctures for obtaining blood specimens on the central area of a newborn's or infant's foot (area of the arch). This may result in injury to the nerves, tendons and cartilage. DO NOT perform skin punctures on the fingers of newborns or infants. c. Warming the skin-puncture site can increase blood flow through the site. A warm, moist towel or diaper at a temperature no higher than 42o C may be used to cover the site for three minutes. d. Clean the skin with an alcohol swab (75%). Wipe off the excess alcohol with dry sterile gauze, and allow the skin to air-dry. Alcohol residue remaining on the skin may dilute the specimen and adversely affect test results. e. To obtain sufficient flow of blood, forcefully puncture the infant's heel with a sterile lancet with tip 2.5 mm long or less or with an automated lancet device. Wipe away the first drop of blood with sterile gauze. f. Hold the infant's heel loosely so not to impede the flow of blood. If bleeding does not immediately occur, massage the lower portion of the leg in a downward direction. Avoid squeezing the area since this dilutes the blood with tissue fluid. g. When a large drop of blood appears, fold back the protective wrap-around cover, and gently touch the filter paper to the drop of blood. Allow a sufficient quantity of blood to soak through to completely fill a preprinted circle on the filter paper. Apply blood only to one side of the filter paper. Examine the opposite side to be sure that blood has penetrated through to make a circle which is approximately the same size as the printed circle. The success lies in allowing the blood drop to grow to its full size and touching with the filter paper when it is about to fall. Repeat this process until all circles are filled. If there is a problem getting a blood flow to fill five circles, get at least three correctly filled circles. Keep the cover folded away from the wet blood while it is being air-dried.
CAUTION: 1. Milking or squeezing the puncture may cause hemolysis of the
specimen and/or a mixture of tissue fluids with the specimen. This type specimen will be called "unsatisfactory, contaminated". 2. Do not layer successive drops of blood in the printed circle. If blood flow diminishes so that circles are not completely filled,
IV- 7

repeat the sampling technique in a new circle. EACH CIRCLE SHOULD BE FILLED WITH ONLY ONE APPLICATION OF FREE FLOWING BLOOD. If not, the specimen will be called "unsatisfactory, unevenly soaked". h. After blood has been collected from the heel of the newborn, the foot should be elevated above the body, and a sterile gauze, pad or cotton swab pressed against the puncture site until the bleeding stops. i. After the blood has been collected, keep the cover folded away from the wet blood. Allow the blood to dry at room temperature for a minimum of three hours by placing the form horizontally on a table top with the wet blood spots over the edge to allow air drying from both sides. Do not place the form inside an envelope until completely dry. Do not put near a heat source, in direct sunlight, or on an absorbent surface. DO NOT TOUCH THE FILTER PAPER WITH YOUR HAND AT ANY TIME. j. Give all the information requested on form 3491. USE BLOCK PRINT. The date of birth, date of collection, time of collection and birth weight are needed to interpret the results. Do not touch the blood spots when completing this step. 2. CAPILLARY COLLECTION -- Although not the preferred method, application of blood collected in sterile heparinized capillary tubes into the preprinted circles of the filter paper is an acceptable alternative to direct application from the heel puncture site, provided the capillary does not touch the filter paper. a. Touch the tip of the heparinized capillary tube to the blood drop formed at the heel puncture site. Blood will flow into the tube by capillary action. Collect approximately 100 ul of blood into the heparinized capillary tube. Use a fresh capillary tube for each blood spot that will be collected on the filter paper. b. After collection of each capillary tube immediately apply the blood to the filter paper in one smooth continuous step without dabbing or other action that might scratch, compress, or indent the paper. Waiting too long before application will allow cells and plasma to separate. c. Apply the blood to each preprinted circle to only one side of the filter paper. Do not try multiple applications. Specimens that exhibit caking or heterogeneous spreading will be called unsatisfactory. d. Observe above mentioned guidelines for preparing infant's heel before and after collection and for specimen handling.
D. Requisition Form The requisition outfit is combined with the collection outfit (form 3491). All of the information requested on the form are important for some of the test result interpretation. The information on the infant's name, birthday, hospital of birth and the physician of record and the telephone number to report abnormal test results are mandatory.
IV- 8

Specimen cards without this information will be classified as "Specimen Unsatisfactory Insufficient Information." BLOCK PRINT all information that is requested. To aid in researching missing reports, keep the submitter's copy of the requisition. This can be useful in identifying missing reports that can be linked to data entry interpretation errors and forms that are incorrectly filled out.
SHIPMENT OF SPECIMENS
Due to the life threatening nature of several of these diseases, the law requires that the specimen collection, testing, retrieval of suspected cases and specific diagnosis all be done before the infant is three weeks old. For this reason the blood specimen must be collected when the infant is no less than forty-eight hours old but not later than one week of age. In order to expedite the testing of the blood sample, and to insure the integrity of the sample, all specimens must be sent to an approved laboratory on the day of collection. Specimens must be completely dry before covering and inserting in the mailing envelope (form 3603). The dried blood spot specimens MUST NOT be packaged in airtight, leak-proof bags. The lack of air exchange in the inner environment of a sealed plastic bag may cause heat buildup, moisture accumulation and/or chemical leaks from the plastic that can damage the specimen integrity. Once collected, specimens can either be mailed to the testing laboratory using the pre-addressed enveloped that is part of the collection outfit or they may be sent by courier. Precaution should be taken that mailed specimens are not put in mail boxes that do not have a daily pickup. The specimen must reach the laboratory within seven days of the collection date or it will be called "unsatisfactory, delayed".
REPORTING AND INTERPRETATION OF RESULTS
Normal results for all tests other than hemoglobins will be reported as WITHIN NORMAL LIMITS. All abnormal results will be reported as POSITIVE or INCONCLUSIVE (galactose), ABOVE NORMAL LIMITS (phenylalanine, tyrosine, methionine, leucine, TSH, or 17-0HProgesterone) or BELOW NORMAL LIMITS (thyroxine), all with a quantitation. Specimens that were previously positive or are Known Cases will always be reported with a quantitative value whether normal or abnormal. Normal hemoglobins will be reported as FA Normal. All heterozygote results (abnormal hemoglobin plus A) will be reported as traits. Any homozygote abnormal (absence of Hgb A) will be reported as a disease. Traits that are not identifiable by the methods used within this lab are reported as: "FA-Variant. Variant Trait Carrier. Confirm Test Required." All tests are performed within the third day of receipt in the lab. Results are available two days after day of testing. All abnormal results are electronically generated and mailed to the hospital of birth and the physician of record on the date of test completion. A letter of interpretation and instructions will accompany the report. All abnormal reports will also be sent to the Genetics Department at Emory University who is responsible for the necessary tracking, confirmation and counseling of positive cases. All normal reports will be mailed after testing is completed for all disease conditions and when the demographic entry is completed which usually takes about three working days. Results of all testing are sent to the Genetics Program Office. The report of any sickle cell disease that is identified will also be faxed to the Program office who, inturn, will relay the information to the follow up centers at Medical
IV- 9

College of Georgia, Augusta and at the Grady Hospital, Atlanta. These centers are responsible for follow-up, confirmation of screening results, treatment of diagnosed cases and for counseling.

NORMAL RANGES:

Phenylalanine Methionine Leucine Tyrosine Galactose TSH T4 17a-0H Progesterone

<4 mg/dl <2 mg/dl <4 mg/dl <12 mg/dl <11 mg/dl <25 uU/ml *See below *See below

*Normal range is dependent upon age and birth weight of infant and may shift due to population being tested. Abnormal T4 levels must be confirmed by elevated TSH levels to be indicative of hypothyroidism. Presently the following levels are recognized.

AGE/BIRTH WEIGHT

NORMAL RANGES

Normal birth weight, < 1 week of age
Normal birth weight, >1 week of age Premature/low birth weight

T4 >7.5 ug/dl
>5.4 ug/dl >4.5 ug/dl

CAH (Age >48 hrs) <45 ng/ml (Age <48 hrs) <80 ng/ml
<45 ng/ml <80 ng/ml

UNACCEPTABLE SPECIMENS
Specimens will be called unsatisfactory to test for the following reasons: 1. Inadequate blood collection (QNS) - A specimen will be considered QNS if at least two
filled and evenly soaked circles are not submitted, or if the blood spot card has an inadequate quantity of blood, either front or back, for the automatic punch assembly to fit within. 2. Oversaturated - Too much blood was allowed to soak onto the filter paper, causing the paper to bend, fold and crumple. May also results in clots on the surface of the paper. 3. Delayed - There is a seven day or more lapsed from date of collection and date received in the laboratory. 4. Contamination - Disinfectant, alcohol, water, tissue fluid or other foreign substance showing to be diluting the specimen. 5. Unevenly Soaked - Multiple applications of blood causing a layering of blood on paper. 6. Capillary - Recognizable as unevenly soaked blood in a circular pattern with roughed up filter paper tracks caused by dragging the tip of the capillary across the surface of the filter paper.

IV- 1 0

7. Crumpled - oversaturation or multiple applications of blood causing the surface of the filter paper to buckle.
8. Obsolete or wrong outfit - Any outfit that is not using the same lot # of filter paper that is presently in use within the lab. This also applies to unfamiliar forms with no lot # given.
9. Roughed Up - Collection of specimen on damaged filter paper so that fibers from paper are standing on end.
10. No Blood - No collection was made. 11. No Information - Specimens without a name (infant or mother) will be reported as
unsatisfactory. When other information is missing but the actual collection is acceptable, certain assumptions will be made, the specimen will be tested, and whereever possible, the results will be released. **A training videotape titled "How to Collect Acceptable Filter Paper Specimens" is available from the Genetics Program upon request. Call (404) 651-7551 for details.
IV- 1 1

IV- 1 2

MICROBIOLOGY/IMMUNOLOGY SERVICES INTRODUCTION
The Microbiology/Immunology Service offers a listing of services we provide to our clients in the areas of bacteriology, immunology, parasitology, mycobacteriology, mycology, and virology. The mission of this unit is to give assistance to public and private health-care providers in their investigation and control of diseases. It is believed that this mission can be best accomplished by the accurate analysis of clinical and reference specimens submitted by the county health departments, hospitals, other clinical laboratories, and physicians in private practice.
In addition to providing this manual, our laboratory services support several statewide investigations. When deemed necessary, both environmental and non-human specimens are tested to help investigate outbreaks of diseases. We also assist the Centers for Disease Control and Prevention (CDC) by participating in surveillance studies and by providing them with the results of our laboratory findings for a number of communicable diseases.
Our Bacteriology Unit uses gas liquid chromatography for analysis of the fatty acid contents of bacterial cell walls as an adjunct to the conventional biochemical tests for bacterial identification. We use the pulsed-field gel electrophoresis (PFGE) technology for the molecular subtyping of a number of different bacteria. Our laboratory has provided valuable information on molecular typing of a number of isolates and has identified strains that have been implicated in a number of foodborne outbreaks. Also, to assist the Food and Drug Administration (FDA) in their AFood Safety Initiatives," our food and enteric section has expanded its services to include detection of Shiga-like toxins (SLT I and II) for enterohemorrhagic Escherichia coli (EHEC), enterotoxin for Staphylococcus aureus, and Clostridium perfringens. The Bacteriology Unit also determines antibiograms for various Salmonella serotypes and all Shigella isolates throughout the state. The Bacteriology Unit, in conjunction with the Albany and Waycross Regional Laboratories, has expanded testing for Chlamydia trachomatis and Neisseria gonorrhoeae (GC) by DNA probes to all Family Planning and STD Clinics throughout the state. We continue to expand our Chlamydia and Gonorrhea testing to include DNA amplification procedures (PCR) for selected sites in the state. To enable us to detect agents of bioterrorism more rapidly, we are in the process of evaluating PCR protocols for these agents. In addition, we are developing PCR protocols for the detection of enterotoxigenic E. coli and Bordetella pertussis.
The Microbial Immunology Unit implemented an enzyme immunoassay procedure in 1997 to confirm the presence of specific syphilis antibodies in RPR-reactive specimens. We continue to offer testing for four hepatitis B virus markers (i.e., surface antigen, surface antibody, core antibody, and e antigen). In addition, a hepatitis B surface antibody quantitative procedure is available to evaluate the level of a vaccine response. In 1998, we implemented testing for hepatitis A instead of referring these specimens to CDC. In 1999, we started parvovirus B-19 testing to expand our viral exanthems testing panel. In 2001, we started offering antibody tests for arboviruses using a panel which includes West Nile Virus.
Our Mycobacteriology Unit continually strives to improve our services by incorporating the latest, appropriate technological advances into our diagnostic assays. To accomplish this, the
IV- 1 3

laboratory now uses quicker and more specific tests in the diagnosis of mycobacteria (e.g., Gen Probe, Bactec MGIT 960, and HPLC), and is capable of identifying most species of mycobacteria. Our skilled mycobacteriologists are committed to reducing our turnaround time for reporting diagnostic and sensitivity results for Mycobacterium tuberculosis; this ensures that reports of acid-fast examinations are available within 24 hours after specimens are received in our laboratory. Additionally, M. tuberculosis is identified in 17 days, on the average, and results of susceptibility tests are provided within 7-14 days after identification of M. tuberculosis. Currently, we are testing four primary drugs (isonazid, rifampin, ehtambutol, and streptomycin) for susceptibility testing.
The Mycology Unit was integrated with Mycobacteriology Unit in 2000 and serves as the state reference laboratory. Our technologists are capable of identifying most, if not all, fungi. This is especially important because, as the number of immunocompromised patients in our population increases, many fungi, which have been considered saprophytes, may become opportunistic pathogens in these patients. The identification of these fungi, as well as the primary pathogens, provides valuable epidemiological information for control of nosocomial and communityacquired infections.
Our Parasitology Unit provides a full range of diagnostic services to all County Health Departments. In addition, our laboratory serves as a reference laboratory to all health care providers. All routine specimens are reported within 12-24 hour turn-around-time of specimen receipt. In addition to testing for intestinal parasites, we examine specimens for blood, tissue, and intestinal parasites, and we identify arthropods of public health importance (e.g., ticks, fly larvae, mites, and lice). The Parasitology Unit routinely examines all fecal specimens for the presence of Cryptosporidium and Cyclospora spp. We also examine blood for all species of malaria and microfilaria. Upon request, urine can be examined for Schistosoma haematobium. We hope to add Microsporidia to our routine diagnostic work in the near future.
The Virology Unit provides testing for HIV antibody by EIA and Western blot. In January 2001, we received funding to perform Viral Load Test (VLT). The latter is a PCR-based procedure that determines the number of copies of HIV-1 RNA in infected patient's blood. Offering VLT expanded our HIV testing by providing the amount of HIV in patient's blood, which will assist clinicians in proper drug selection for treating their patients. The Virology Unit identifies other viruses such as influenza and herpes by culture and specific detection procedures. In addition, all potentially rabid domestic and wild animals are tested for rabies when there is a suspected human or domestic animal exposure. Every year during flu season, our laboratory participates in a statewide surveillance to determine the predominant type of flu virus in circulation, throughout the state. We use electron microscopy for preliminary identification of Norwalk-like viruses, enteroviruses, rotaviruses, and adenoviruses. We participate in the Viropharma/ Epidemiology Surveillance for enteroviruses.
Our ability to expand the aforementioned services and offer more to the community has been made possible, in part, through financial support from federally funded programs dedicated and delivered to our laboratory by the Emerging Infection Program, and the STD, the TB, and the
IV- 1 4

Immunization programs. We participate in the Viropharma /Epidemiology surveillance for enteroviruses. To ensure that our laboratories continue producing high-quality results, we have expanded our current quality assurance (QA) program to include the tracking of agencies and individuals that submit "unsatisfactory" specimens. This will better enable us to communicate with these submitters as to how they can improve the quality of the specimens they submit to us. Other aspects of our QA program include our continued participation in proficiency testing, which is offered through the College of American Pathologists and the American Association of Bioanalysts for all our laboratory units. In addition, our HIV and Microbial Immunology Units participate in proficiency testing offered by CDC. The Virology Unit participates in the Rabies Proficiency Testing offered by the Wisconsin State Laboratory of Hygiene, and Mycobacteriology Unit participates in the Sensitivity Assay Proficiency Testing offered by the CDC. In summary, we are constantly endeavoring to provide the most accurate and the most reliable laboratory services possible for the purpose of maintaining and improving the overall health of our state, our community, and its individual members.
Mahin M. Park, Ph.D., HCLD Clinical Laboratory Service Director Immunology/ Microbiology Services E-mail: mpark@gdph.state.ga.us Telephone No: (404) 327-7905
IV- 1 5

IV- 1 6

Bacteriology Unit
Unit Personnel
Program Assistant - Deborah Wilson Associate - Leith Cobb, M.S. Manager - Marsha Ray, M.S.
IV- 1 7

IV- 1 8

BORDETELLA PERTUSSIS 404-327-7990
INTRODUCTION
The Bacteriology Unit accepts cultures for the isolation of both Bordetella pertussis and B. parapertussis, nasopharyngeal swabs in charcoal-blood transport medium for both agents, and slides for direct fluorescent antibody (FA) testing for B. pertussis only. Specimens may be sent from public and private health care providers. Pulsed-field gel electrophoresis (PFGE) will be performed on all B. pertussis isolates to evaluate similarities between strains, and antibiotic susceptibility to erythromycin will be performed on all isolates as well. We are in the process of developing and evaluating a PCR protocol for the detection of B. pertussis.
SPECIMEN COLLECTION/LABELING/REQUISITION FORM
Nasopharyngeal swabs are the specimens of choice, and they should be collected as soon as possible after onset of illness, preferably before antibiotic treatment. Calcium alginate swabs are superior to other types of swabs and should be used to collect specimens as follows: pass swab very gently through the nostril until it reaches the posterior nares and leave in place for 15 to 30 seconds (this may induce a cough and in practice only a few seconds may be possible). Collect a second swab from the contralateral nostril in the same manner.
A. Specimen for Culture: Inoculate the culture plate first to avoid contamination if both a smear and culture are being submitted. Select one of the following procedures immediately after collection (the choice dependent upon delay in transport - see Shipment of Specimens Section): (1) Inoculate specimen directly at bedside onto a Regan-Lowe plate.* Rotate swab over the first quadrant, and streak the remaining plate for isolated colonies using a sterile loop; (2) Place swab in a fatty acid-free solution of 1.0% Casamino Acids, available commercially. (3) Place swab in a charcoal-blood transport medium.* Label plate or transport tube with the patient=s name or other unique identifier and date of specimen collection.
*Regan-Lowe plates and tubes of charcoal-blood transport media may be obtained from the Bacteriology Laboratory. To obtain these items, special arrangements must be made in advance of specimen collection. They are also available commercially. Plates and transport medium should be stored refrigerated and warmed to room temperature before use.
B. Specimen for Slides: Prepare 2 dime-sized smears on each of 2 microscope slides (one slide per nostril). Use frosted-end slides with prestamped circles if possible (frosted side up). Label slide holder
IV- 1 9

with the patient=s name or other unique identifier and date of specimen collection (avoid using wax pencil or gummed labels on slides).
C. Culture (B. pertussis isolated at submitting laboratory): 1. Inoculate a pure culture onto a plate of charcoal agar with horse blood, such as Regan-Lowe medium, and incubate at 35o C under high humidity. Schedule subculture so that time between optimal growth and transport of culture is <24 hours. 2. Examine medium beginning after 2 days incubation until confluent growth appears in the first quadrant of the plate. 3. Using a Dacron swab, aseptically harvest all growth from the first quadrant of the plate by sweeping the swab head through the area of confluent growth while rotating the swab shaft. Immerse swab containing harvested growth 2mm deep into the agar of a charcoal-blood transport tube, warmed to room temperature. 4. Aseptically cut the swab shaft flush with the top of the transport tube and replace cap. 5. Label transport tube with patient identifier information. 6. Maintain additional subculture(s) on plates at submitting laboratory until viability of referred culture is confirmed by the Bacteriology Unit.
Requisition Form If both culture and direct FA are requested, complete form #3410 and include the following information: (1) Unique patient identifier (name or number). (2) Date of specimen collection. (3) Test requested, such as culture for B. pertussis and B. parapertussis and direct FA for B.
pertussis. (4) Submitter=s name and address. (5) Name and telephone number of clinician to contact. (6) Source of specimen, such as nasopharyngeal. (7) Patient=s race, sex, age, and address, if available. (8) Brief clinical history, if available.
If only direct FA is requested, use form #3415 and include the above information. If an isolate is submitted, complete form #3410.
The patient identifier (name, number, or both) indicated on the requisition form should match that written on the slide holder, transport tube, or culture. Unlabeled specimens will not be tested.
SHIPMENT OF SPECIMENS AND CULTURES (See pages II-1 - II-4 of this manual for recent changes in federal shipping guidelines)
A. Slides: Place slides securely in the plastic slide holders provided (outfit #0525, available from Laboratory Services and Supply, 404-327-7920). Place plastic holder in a plastic biohazard bag. Insert requisition form in the pouch in the front of the bag. Place the bag
IV- 2 0

with form affixed in the orange-labeled cardboard mailing container (Decatur address). Seal the lid of the outside container with tape. Send by first class mail, common carrier, or courier. If there is any delay in shipment, slides may be held at room temperature.
B. Nasopharyngeal Specimens for Culture: The method of shipment is dependent upon the selection of transport media used and the length of time required to arrive at the Bacteriology Unit. (1) Inoculated plates must be incubated at 35o C with increased humidity or transported (room temperature) to the Bacteriology Unit immediately by courier. (2) Specimens in tubes of charcoal-blood transport media should be transported (room temperature) to the Bacteriology Unit immediately by courier, or if there is any delay in shipment, they should be stored and sent refrigerated (with ice packs) by first class mail, common carrier, or courier. (3) Specimens in Casamino Acids must arrive within 2 hours after specimen collection. Under these conditions, they may be sent at room temperature.
C. Isolates inoculated into charcoal-blood transport media may be shipped at room temperature via Federal Express using pre-printed labels (available from the Bacteriology Unit).
REPORTING AND INTERPRETATION OF RESULTS
Results of direct FA testing are completed the day of receipt if received by 1:00 pm, Monday through Thursday, or by 2:00 pm on Friday. Results of both negative and positive reports are telephoned to the submitter the day of testing. Nasopharyngeal smears are reported positive for Bordetella pertussis if there are > 5 organisms present with typical cellular morphology and intense fluorescence. Due to shortage of quality reagent, B. parapertussis FA testing is confined to confirmation of positive cultures for this organism.
Cultures are held 7 days from the date of inoculation and are read daily. Nasopharyngeal swabs received in transport medium tubes are inoculated immediately onto Regan-Lowe plates when received, placed back into the transport medium and incubated an additional 48 hours, and then again inoculated onto Regan-Lowe plates. Each plate is held 7 days, so the total turnaround time for reporting swabs received in transport medium is 9 days. After the final day of incubation, if there are no colonies typical of B. pertussis or B.parapertussis present, the culture is reported negative for these organisms. A positive culture report is based upon typical cellular and colonial morphology and is confirmed by fluorescent antibody testing. Positive cultures or cultures overgrown with mold or normal flora are reported immediately upon detection, and results are telephoned to the submitter.
Both culture and direct FA procedures are recommended for diagnosis of B. pertussis whenever possible. AFalse negative@ FA results may occur from low numbers of organisms present in nasopharyngeal secretions. The FA test is most valuable during the early phase of illness and before antibiotic treatment when the largest number of organisms are being shed. Positive FA results should be considered presumptive. As with any subjective test, Afalse positive@ FA results
IV- 2 1

are possible. Only highly experienced staff in the Bacteriology Unit reads slides and reports results to minimize false positives. AFalse negative@ culture results may follow from any procedures that render the organisms nonviable, such as improper handling of plates and transport medium after collection or prolonged antibiotic treatment. The FA test will detect nonviable organisms. A positive culture result is the most reliable. UNACCEPTABLE SLIDES AND CULTURES 1. Smears that are too thick or too thin for accurate interpretation (these slides will be read
but reported as unsatisfactory and the reason will be noted on the report). 2. Slides broken in transit. 3. Cultures overgrown with mold or normal flora. 4. Cultures or transport medium improperly submitted (see above for the recommended
procedure). 5. No patient identifier on specimen or culture.
IV- 2 2

CHLAMYDIA/GONORRHEA DNA PROBES 404-327-7990
INTRODUCTION
Chlamydia (C.) trachomatis is the most common treatable sexually transmitted infection affecting females of reproductive age in the United States today, with an estimated four million new cases each year. Up to 80% of infected females have few or no symptoms, and asymptomatic infection in females can persist for up to 15 months. Complications of untreated chlamydial infection in females include: acute pelvic inflammatory disease; ectopic pregnancy; chronic pelvic pain; and infertility.
Gonorrhea affects males and females from symptoms of purulent discharge in males, a few days after exposure, to very mild symptoms in females. Symptoms may pass unnoticed with a consequence that asymptomatic carriers contribute significantly to the public health problem of gonorrhea.
The Bacteriology Unit uses Gen-Probe Pace 2 reagents and DNA Probe methodology for chlamydia and gonorrhea screening, and when indicated, uses the Probe Competitive Assay (PCA) by Gen-Probe for confirmation.
SPECIMEN COLLECTION/LABELING/REQUISITION FORM
Pap smears should be collected after specimens for DNA probes. Female endocervix and male urethra are the only specimens FDA approved for the Gen-Probe Pace 2 test. Throat, rectum, and vaginal specimens should not be submitted for DNA probes.
Use the Gen-Probe Pace 2 specimen collection kits supplied by the District or County services and supply representative, or contact Teresa Edwards at (404) 657-3100 to place an order. The kits are color-coded B pink for females, and blue for males.
CLIENT TESTING CRITERIA:
Family Planning Clinics: All females age 29 years or younger who receive a pelvic exam during a visit (initial, annual or comprehensive medical only) will be screened for chlamydia. A female will only be screened once per calendar year for chlamydia unless she has clinical signs or symptoms of chlamydia (cervicitis/MPC, friable cervix, cervical ectopy, abdominal pain, abnormal bleeding, dyspareunia or dysuria) or a new sex partner or multiple sex partners in the past 60 days. All females 30 years and older who meet these criteria will also be screened for chlamydia.
STD/General Clinics: All females age 10-29, who receive a pelvic exam during a visit, will be screened for chlamydia. This includes rescreening females who are returning for medical problems, receiving more than one pelvic exam a year and/or are currently on antibiotics. All females 30 years and older who present with clinical
IV- 2 3

signs or symptoms of chlamydia (cervicitis/MPC, friable cervix, cervical ectopy, abdominal pain, abnormal bleeding, dyspareunia or dysuria) or have a new sex partner or multiple sex partners in the past 60 days will also be screened for chlamydia. Male clients presenting for services should also be screened for chlamydia.
Teen Clinics : All females who receive a pelvic exam will be screened for chlamydia. This includes rescreening females who are returning for medical problems, receiving more than one pelvic exam a year and/or are currently on antibiotics. Males should also be screened.
All female/male clients screened for chlamydia will also be screened for gonorrhea.
Females with cervical stenosis should be included in the chlamydia/gonorrhea screening.
If the client does not have a cervix, she will not be included in the chlamydia screening.
SPECIMEN COLLECTION
Endocervical females 1. Moisten the speculum with warm water (do not use any other lubricant), insert the
speculum, and visualize the cervix. 2. Remove excess mucus from the cervical os and surrounding mucosa by gently wiping
with one of the swabs provided in the kit. 3. Discard cleaning swab. 4. Insert other swab from collection kit one to one and one-half centimeters into the
endocervical canal. 5. Rotate the swab slowly 180 degrees (at least 10 seconds) in the endocervical canal to
ensure adequate sampling. Withdraw swab carefully; avoid any contact with vaginal mucosa. 6. Insert this second swab (collection swab only) into the GEN-PROBE transport tube. Snap off shaft at score line or cut shaft to fit tube. Cap tube tightly. Legibly label tube with client=s name, patient ID# and date of collection. UNLABELED SPECIMENS WILL NOT BE TESTED.
Urethra males 1. Patient should not have urinated for at least one hour. 2. Insert swab from collection kit two to four centimeters into urethra. 3. Once inserted, rotate swab gently at least one full rotation using sufficient pressure to
ensure swab comes into contact with all urethra surfaces. Allow swab to remain inserted for two to three seconds. 4. Withdraw swab.
IV- 2 4

5. Insert collection swab into the GEN-PROBE transport tube. Snap off shaft at score line or cut shaft to fit tube. Cap tube tightly. Legibly label tube with client=s name, patient ID# and date of collection. UNLABELED SPECIMENS WILL NOT BE TESTED.
Requisition Form 1. Use the Chlamydia and Gonorrhea requisition form #3568 (Rev. 8-00). 2. Fill out the form completely by printing or typing legibly. Only legible information can
be entered correctly into the laboratory database. Incomplete or illegible information may delay your results. Do not use computer-generated labels for patient information. 3. Information required is as follows: a. Submitter information (submitter code, submitter address, and phone number). b. Patient information (name, patient ID number, county of residence, zip code,
State, race, ethnicity, gender, date of birth). c. Specimen information (test requested, reason for test, date collected, source of
specimen, specimen status). 4. Tear off the top section of form (white copy) and mail to the laboratory with the
specimen, making sure the names on the specimen and form are EXACT matches. Retain the other two copies of the form (pink and yellow) for clinic and program use. 5. Chlamydia and Gonorrhea Laboratory Submission forms should be ordered as indicated by the STD Program Office.
SHIPMENT OF SPECIMENS
For best results, specimens should be transported to the laboratory on the date of collection; however, if this is impossible, specimens may be kept at room temperature and shipped as soon as possible. Specimens over seven days old at the time of arrival in the laboratory will be reported unsatisfactory.
1. Chlamydia/Gonorrhea Probe specimens may be transported at room temperature. Use the specimen transport cans and Decatur address labels (available from the laboratory).
2. Be sure the caps on the transport tubes are secure, and wrap each specimen in absorbent packing material. Place the wrapped specimen inside the aluminum can, and close the can securely.
3. Wrap the completed requisition form around the aluminum can and secure it with a rubber band.
4. Place the aluminum can inside the labeled (Decatur address) fiberboard can, close, and secure the lid with tape.
5. An alternate shipping method may be utilized by substituting the BIOHAZARD BAG for the inner aluminum container. If this method is chosen, the matching requisition forms should be placed in the pouch located in the front of each bag.
6. Specimens may be mailed or shipped by the method most convenient and expedient.
IV- 2 5

REPORTING AND INTERPRETATION OF RESULTS
The goal of the Bacteriology Unit is to test and report all Chlamydia/Gonorrhea Probe specimens within a 48-hour turnaround period, unless confirmation testing is required (these specimens are reported the following business day). An electronic copy of all positive Chlamydia and Gonorrhea reports is transmitted to the State Sexually Transmitted Disease (STD) Program. A hard copy of all positives is also mailed to the State STD Surveillance Office.
Results are reported as follows:
POSITIVE B Nucleic acid for C. trachomatis and/or N. gonorrhoeae was detected in the specimen, and as indicated, confirmed by Probe Competitive Assay.
NEGATIVE B No evidence of nucleic acid of C. trachomatis and/or N. gonorrhoeae was found in the specimen.
INDETERMINATE B Results of repeat testing are equivocal. Submit another specimen.
UNSATISFACTORY B Specimen compromised in some manner making it unsatisfactory for testing. The reason for each Unsatisfactory result will be listed on the report form.
UNACCEPTABLE SPECIMENS
Specimens will be reported UNSATISFACTORY for the following reasons: 1. No patient identifier on the specimen, or discrepancy between identifier on the specimen
and requisition form. 2. Source other than cervix or male urethra. 3. Two swabs received in the collection outfit. 4. No solution in the collection outfit. 5. No swab, or improper swab (not from Gen-Probe kit) in the collection outfit. 6. Specimen greater than seven days old from date of collection when received. 7. Grossly bloody specimen. 8. Collection kit expired. 9. No specimen received. 10. Medical/legal specimens (DNA probes are not approved for medical/legal cases).
IV- 2 6

ENTERIC BACTERIOLOGY 404-327-7990
INTRODUCTION
The Bacteriology Unit examines feces and other specimens for the presence of enteric pathogens, namely Salmonella serotypes, Shigella, Campylobacter, Aeromonas species, Yersinia enterocolitica, and E.coli O157:H7, on a routine basis. Testing for Shiga-like toxin (SLT) will be done on all bloody stools and on all stools when E.coli O157 is requested. Stool specimens for other foodborne etiologic agents, such as Staphylococcus aureus, Vibrio spp., and Clostridium perfringens, will be tested if the patient=s clinical history and the epidemiological data warrant (see section on Foodborne Illness). Environmental samples may be accepted for enteric culture, but only when implicated in cases of human illness or by prior consultation.
All isolates of Salmonella, Shigella, Campylobacter, E.coli O157:H7, Yersinia enterocolitica, and Vibrio. recovered from specimens by other clinical laboratories in Georgia should be referred to the Bacteriology Unit, either directly or through the Emerging Infections Program (EIP) site. Referred isolates will be further characterized by various methods, such as biochemical reactions, serogrouping/serotyping, cell wall fatty acid analysis, Pulsed-field gel electrophoresis (PFGE), and/or antibiotic susceptibility testing, depending upon the organism. Tests for SLT will be performed on all cultures when E.coli O157 is requested. A multiplex PCR assay is available for enterotoxigenic E. coli by special arrangement. These services are used in conjunction with epidemiological investigations and surveillance, and are offered at no charge. Tests for occult blood and fecal WBC counts are not performed at the GPHL.
SPECIMEN COLLECTION/LABELING/REQUISITION FORM
A. Feces Specimens for Salmonella, Shigella, Campylobacter, Aeromonas, Yersinia, E.coli O157, Listeria, Staphylococcus aureus, and Vibrio: 1. Feces specimens for the above agents should be collected in the Para-Pak C&S outfit, salmon-colored top (do not use the Parasitology O&P kit, blue and whitecolored top, because it contains formalin that kills bacteria). Collect freshly passed feces as soon as possible after onset of illness and before antimicrobial therapy has been initiated (stools for S. aureus must be collected within 24 hours after onset). Select portions containing blood or mucous, if present. Use the Aspoon@ in the lid of the collection vial to facilitate placing a portion of the feces into the vial, add specimen only to the red line on the vial, tighten the cap securely, and invert several times. The solution in the vial should be salmon colored before the specimen is added. Two to three specimens collected on different days may be necessary for diagnosis. 2. Rectal swabs containing detectable feces may be collected and placed in a culturette with Stuarts, Cairy-Blair, or other commercially available transport medium (not provided by the GPHL), if a feces specimen cannot be obtained. Pathogens are less likely to recovered from rectal swabs than from feces. 3. Store and ship at room temperature.
IV- 2 7

B. Feces specimens for Clostridium perfringens, C. botulinum, and Bacillus cereus: 1. For these agents, collect fresh stool specimens and place in a leak-proof, noncrushable, clean container (not provided by GPHL). Do not use the enteric ParaPak C&S stool culture outfit. 2. For C. perfringens and B.cereus, stool specimens must be collected within 48 hours from the time symptoms begin. 3. Store and ship refrigerated.
C Each stool specimen must be clearly labeled with the patient=s name and accompanied by a properly completed isolation form #3416 (Feces Culutre for Bacterial Enteric Pathogens). The form must include the following information: 1. Patient identifier (name or number). 2. Date of specimen collection. 3. Agent suspected, if applicable. 4. Submitter=s name and address. 5. Symptoms.
D. Referred Cultures (for identification) Submit an overnight, pure culture of the isolated bacteria on carbohydrate-free media (TSA and TSI are acceptable). Label tube with the patient=s name and complete the Isolation for Identification form #3410. The form must include the following information: 1. Patient identifier (name or number). 2. Date of collection. 3. Source of specimen. 4. Agent suspected. 5. Submitter=s name and address. If possible, please include any clinical data, cultural characteristics, biochemical reactions, or serology.
The patient identifier (name, number, or both) indicated on the requisition form should match that written on the specimen or culture. Unlabeled specimens or cultures will not be tested.
SHIPMENT OF SPECIMENS AND REFERRED CULTURES (See pages II-1 - II-4 of this manual for recent changes in federal shipping guidelines).
Mailing containers for submitting fecal specimens and referred enteric cultures are available from Laboratory Services and Supply (404) 327-7920. For stool specimens order #0555, Astool culture,@ and for cultures order #0505, Aculture referral for identification.@
To facilitate handling, the following should be observed:
1. Wrap kyfax absorbent around the specimen/culture and place in the biohazard bag provided. Put the correct requisition form (stools for isolation, #3416, or cultures for serotyping or identification, #3410) in the pouch located in front of the bag.
IV- 2 8

2. Place the biohazard bag in the cardboard mailing container with the Decatur address label (orange). Seal the lid of the outside can with tape.
3. Ship specimens as soon as possible after collection. If there is a delay in transport, keep the specimen at room temperature; do not refrigerate (except as noted above for stool specimens for C.perfringens, C.botulinum, and B.cereus).
4. Specimens and referred cultures should be mailed first class, shipped by common carrier, or delivered to the Laboratory by courier.
5. When large numbers of specimens are expected (such as in an outbreak), please alert the Bacteriology Unit by telephone (404) 327-7990 before mailing so adequate amounts of media will be available for processing.

REPORTING AND INTERPRETATION OF RESULTS

Negative stool specimen results are reported within 2 to 4 working days. Preliminary positive specimen results are also reported within 1 to 4 working days and are telephoned to the submitter; final results are reported within 4 to 6 working days.

Serotyping and confirmation or identification results are usually reported within 3 to 5 working days for Salmonella, Shigella, Aeromonas, Vibrio, and Yersinia spp., within 4 to 6 working days for E.coli O157:H7, and up to 10 working days for Campylobacter.

A negative stool culture report reflects the organisms for which the stool specimen was routinely examined: ANo Salmonella, Shigella, Campylobacter, Aeromonas, Yersinia enterocolitica, or E.coli O157:H7 found.@ Other organisms will be reported, as appropriate, per request. The
results of SLT testing will be reported when performed.

The following enteric pathogens, whether isolated from stool specimens or submitted as referred

cultures are identified/confirmed to the species or serotype level:

Salmonella sp. or serotype

Aeromonas sp.

Shigella sp. and serotype

Vibrio sp.

Campylobacter sp.

Yersinia enterocolitica and serotype

E.coli O157 positive/negative, H7 positive/negative, and/or SLT positive/negative

UNACCEPTABLE SPECIMENS

1. Specimens submitted in wrong preservative, e.g., PVA or 10% formalin. 2. Refrigerated specimen for Shigella. 3. Multiple specimens collected on the same day (only one specimen will be tested). 4. No patient identifier on specimen or culture. 5. Specimens received more than 7 days after collection (they will be tested, but a
disclaimer will be added to the report indicating that negative results are questionable). 6. Swab submitted in Para-Pak C&S outfit.

IV- 2 9

IV- 3 0

FOODBORNE OUTBREAKS 404-327-7990
INTRODUCTION
The Bacteriology Unit assists physicians and county health department officials in the diagnosis and epidemiological investigation of outbreaks of suspected foodborne illness. The laboratory examines food, feces, and other epidemiologically implicated specimens for the presence of disease-producing bacteria or toxins. Food samples from single cases of suspected foodborne illness will not be examined with the exception of suspected botulism cases. The Georgia Environmental Health and Injury Control Branch (404-657-6534) must be notified by the County Health Department in which the suspected outbreak has occurred, unless botulism is suspected, in which case the Georgia Epidemiology and Prevention Branch (404-657-2588) should be notified. The Bacteriology Laboratory must be advised by either the Environmental Health and Injury Control Branch or the County Health Department of the forthcoming samples, the method of shipment, and the expected time of arrival. This will facilitate the necessary preparations that must be made for processing and examining the samples. Suspect food samples from commercial or retail stores should be referred to the Georgia Department of Agriculture (404656-3621).
When submitting food samples, clinical signs and symptoms, incubation periods, duration of illness, the type of food being submitted, and other pertinent clinical or epidemiological data, must be indicated. This information should also be appropriate for the suspected organism before testing will be initiated. Feces and other epidemiologically implicated specimens, as deemed appropriate by the investigating environmental health specialist, may also be tested.
SPECIMEN COLLECTION/LABELING/REQUISITION FORM
All food items must be clearly labeled as to contents and type of food. Fecal or other specimens should be clearly labeled with the patient's name or other unique identifier and indicated as being associated with the outbreak under investigation. Unlabeled specimens will not be tested.
A. Food All food specimens (25 grams minimal, preferably 100 grams ) should be collected under sterile conditions, placed in sterile plastic bags (whirlpacks) or other suitable leakproof containers, and refrigerated. It is the responsibility of the environmental health specialist who collects the specimens to ensure that each food item is accompanied by a completed Food Report (form #3450). The following minimum information must be included: source of sample; type of sample; date collected; incubation period; clinical symptoms; organism suspected; and submitter's name and address.
B. Fecal Specimen 1. Enteric Pathogens and Staphylococcus aureus: Refer to the Enteric Bacteriology section of this manual for instructions pertaining to collecting and shipping specimens in the ParaPakTM stool culture outfit. Do
IV- 3 1

not refrigerate these stool specimens . Ensure that each specimen is properly collected and labeled and submitted with form #3416. Indicate the enteric pathogens suspected on this form. 2. Clostridium perfringens and Bacillus cereus: Collect a stool specimen within 48 hours from the time symptoms begin, place in a leak-proof, non-crushable container and refrigerate immediately. Label the specimen with the patient's name or other unique identifier. Do not use the enteric ParaPakTM stool culture outfit, as this will result in erroneous spore count results. Form #3416 must be filled out and C. perfringens or B. cereus, depending upon the request, written on the form as the agent suspected.
C. Food Handlers 1. S. aureus: Swab the infected area and/or anterior nasal membranes. Place the swab in a culturette with Stuarts, Cairy-Blair, or other commercially available transport medium. Label specimen with the patient's name or other unique identifier and complete form 3410 (Isolation for Identification). 2. Enteric Pathogens: Follow procedure in section B.1, above.
D. Environmental Swab the suspected area(s) and submit as in C. above.
E. Botulism (testing performed at CDC) - Also see Section C, AShipment of Specimens@ 1. Contact the Bacteriology Unit (404-327-7990) for the initial coordination of specimen collection. 2. The submitter must also contact the Ga. Epidemiology and Prevention Branch, (404-657-2588), who will assess, through epidemiological and patient clinical history, if testing for botulism is warranted. 3. If approval is given, Epidemiology will notify both the Bacteriology Unit and CDC that specimens will be coming. 4. Feces, food, and bowel contents (at autopsy) may be examined directly for C.botulinum specific neurotoxins A through G. These specimens may also be cultured for C. botulinum, and if an isolate is recovered, it may subsequently be tested for the specific neurotoxins present. 5. For infant botulism, the above procedures may be followed, but the most rapid method is by detection of neurotoxin in feces. 6. Collect feces and food samples in leak-proof, non-crushable containers, refrigerate immediately, and keep refrigerated after collection.. 7. Complete a CDC form #50.34 (available from the Bacteriology Unit) for each specimen or food sample submitted.
SHIPMENT OF SPECIMENS
A. Food: Keep food samples refrigerated. Do not freeze or use dry ice. However, if a food is received frozen, keep it frozen and ship with dry ice. Using a sturdy, waterproof shipping container, place samples and refrigerant in the shipper. Place form(s) 3450 and
IV- 3 2

other epidemiological and clinical information in an envelope attached to the outside of the shipper, or put the form(s) in a separate waterproof plastic bag inside the shipper with the food. Deliver sample(s) to the Bacteriology Unit by courier or ship by the most rapid method. Always notify the Bacteriology Unit of the expected time of arrival.
B. Feces and Other Types of Clinical Specimens (except those for botulism) Feces for enteric pathogens and Staphylococcus aureus should be shipped according to the instructions in the Enteric Bacteriology section of this manual. They should not be sent refrigerated. Specimens for Clostridium perfringens and Bacillus cereus should be sent refrigerated and may be delivered to the Bacteriology Unit by courier or shipped separately by the usual transportation or mailing systems available.
C. Botulism 1. Specimens may be sent to the Bacteriology Unit for referral to CDC or sent directly to CDC, as deemed necessary. 2. All specimens for botulism must be shipped with refrigeration.
REPORTING AND INTERPRETATION OF RESULTS
Examination of food samples and fecal specimens may require up to seven working days depending upon the suspected etiologic agent. Positive reports will reflect the etiological agent(s) which have been detected and/or enumerated and may include one or more of the following: Salmonella sp. or serotype, Shigella sp. serotype, Campylobacter sp., E. coli 0157:H7, Clostridium perfringens, Staphylococcus aureus, Bacillus cereus, Vibrio sp., or other possible pathogens. Negative reports will be issued in those cases where the suspected organism was not found. "Test Not Performed" will be indicated when the foodborne organism requested for isolation and Gram stain does not fit the epidemiological and clinical data indicated. Gram stains are performed and reported when requested, and also if the interpretation of these results can assist in the assessment of samples for the suspected organism(s). Toxin studies may be performed in appropriate cases: enterotoxin for S. aureus, enterotoxin for C. perfringens, and SLT for E. coli, and may take an additional two to three working days. Swab results from food handlers are usually reported within three days. Pulse-field gel electrophoresis will be done on E. coli O157:H7, Listeria monocytogenes, Salmonella, and Staphylococcus aureus isolates, and may require an additional two to three days for completion.
Confirmation that a certain food sample is involved in an outbreak is made by detecting the same pathogen (or toxin) in patient specimens and also in suspect food(s). See Table, AGuidelines for Confirmation of Foodborne-Disease Outbreaks of Bacterial Origin,@ on pages IV-35 through IV39.
UNACCEPTABLE SPECIMENS
Unacceptable food specimens will be assessed on an individual basis in conjunction with the Environmental Health and Injury Control Branch.
IV- 3 3

IV- 3 4

Guidelines for Confirmation of Foodborne-Disease Outbreaks of Bacterial Origin

Etiological Agent
Bacillus cereus Emetic toxin (heat stable)

Incubation Period
1 6 h

Bacillus cereus Diarrheal toxin (heat labile)

6 24h

Campylobacter

2 10d; usually 2 5d

Clostridium perfringens 6 24h, median 12h

Clinical Syndrome

Required Collection Submis- How to

Specimen Vial

sion Form Ship

Criteria for Outbreak Association

Nausea & vomiting, sometimes diarrhea. Fever rare. Duration of < 1 day.

Stool w/in 48 h after onset
Food

Clean container
Zip-lock bags; clean container

#3416 #3450

Refrigerated

Isolation of organism from > 2 people.

Refrigerated

Isolation of > 105 organisms/g from implicated food, provided specimen properly handled.

Watery diarrhea, abdominal cramps; sometimes nausea & vomiting; fever rare. Duration of < 1 days.

Same as for emetic toxin

Same as for emetic toxin

Same as for emetic toxin

Same as for emetic toxin

Same as for emetic toxin

Diarrhea (oftern bloody), fever, abdominal pain. Duration 1 - 5 days.

Stool Food

Para-Pak #0555
Zip-lock bags; clean container

#3416 #3450

Diarrhea, abdominal cramps; vomiting, fever, & chills rare. Short duration of < 1 day.

Stool w/in Clean 48h after container onset

#3416

Food

Zip-lock bags; clean container

#3450

Ambient Temp.
Refrigerated

Isolation of organism from > 2 people.
Isolation of organism from implicated food.

Refrigerated
Refrigerated

Isolation of > 105 organisms/g from > 2 people; Demonstration of enterotoxin from > 2 people.
Isolation of > 105 organisms/g from implicated food; isolation of enterotoxin-producing strain of C. perfringens

IV- 35

Etiological Agent

Incubation Period

Clinical Syndrome

Required Collection Submis- How to

Specimen Vial

sion Form Ship

Criteria for Outbreak Association

Clostridium botulinum Preapproval by Georgia Epidemiology & Prevention Branch and Prearrangement with CDC required.

2h - 8d; usually 12 - 48h

Illness of variable severity; nausea, vomiting, abdominal pain, & diarrhea may appear early. Headache, diplopia, blurred vision, & bulbar weakness common; paralysis, which is usually descending & bilateral may progress rapidly.

Serum Stool* Gastric Contents Food

Clean vials and/or container

CDC Form #50.34 one per specimen

Refrigerated

Detection of botulinal toxin in serum, stool, gastric contents, or implicated food; Isolation of organism from stool or intestine. Isolation of C. botulinum, but not the toxin, in a food consumed by a patient with suspected botulism is generally inadequate for confirming the illness.

Enterohemorrhagic E. coli (O157:H7 and others)

1 10d; usually 3 4d

Diarrhea (often bloody), abdominal cramps (often severe), little or no fever.

Stool** Food

Para-Pak #3416 #0555

Zip-lock bags; clean container

#3450

Ambient Temp.
Refrigerated

Isolation of SLT-producing E. coli (O157:H7 or others) from > 2 people, same subtype (PFGE).
Isolation of SLT-producing E. coli (O157:H7 or others) from implicated food, same serotype/subtype as that found from stool specimens.

*Best for infant botulism. **Tests for detection of SLT from an overnight broth culture, or directly from a fresh stool, will be performed. The presence or absence of the SLT will be reported. These results must be interpreted according to the total clinical picture.

IV- 36

Etiological Agent

Incubation Period

Listeria monocytogenes Invasive disease 2-6 wks

Clinical Syndrome
Meningitis, neonatal sepsis, fever

Diarreal disease Unknown

Diarrhea, abdominal cramps, fever

Salmonella

6h - 10d, usually 6 - 48h

Diarrhea, abdominal cramps, fever, chills, vomiting, headache, anorexia, malaise. Duration of several days.

Required Collection Submissio How to

Specimen Vial

n Form Ship

Criteria for Outbreak Association

CSF, bld., placenta, amniotic fld, fetal tissue

Sterile vial and/or Container

#3410

Pure Culture

Culture Referral Outfit #0505

#3410

Stool

Para-Pak #3416 #0555

Food
Stool Food

Zip-lock bags;clea n container
Para-Pak #0555
Zip-lock bags;clea n container

#3450
#3416 #3450

Refrigerated arrive w/in 48 hr.
Ambient Temp.

Isolation of organism from normally sterile site, same serotype/subtype as implicated food.
Confirmation of identification of organism & of same serotype/subtype as implicated food.

Ambient Temp.
Refrigerated
Ambient Temp. Refrigerated

Isolation of organism, same serotype /subtype: (a) from > 2 people exposed to implicated food, or (b) as isolate recovered from implicated food.
Isolation of organism from implicated food, same serotype/subtype as isolates from > 2 people.
Isolation of organism, same serotype/subtype, > 2 people.
Isolation of organism from implicated food, same serotype/subtype as that found from stool specimens.

IV- 37

Etiological Agent Staphylococcus aureus

Incubation Period
30 min 8h, usually 2 4h

Shigella

12h - 6d; usually 2-4d

Vibrio cholerae O:1 and O:139

1 5d

Clinical Syndrome

Required Collection Submis- How to

Specimen Vial

sion Form Ship

Vomiting, diarrhea.

Stool w/in Para-Pak

Short duration of not 24h after #0555

more than a day or two. onset

#3416

Nasal or Wound Swab food handler

Commercial swab outfit (not supplied)

#3415

Food

Zip-lock bags;clea n container

#3450

Ambient Temp.
Ambient Temp.
Refrigerated

Diarrhea (often bloody), fever, abdominal cramps. Duration of several days.

Stool Food

Sudden onset, profuse watery diarrhea, often w/ mucus, abdominal pain, rapid dehydration.

Stool Food

Para-Pak #3416 #0555

Zip-lock bags;clea n container

#3450

Para-Pak #3416 #0555

Zip-lock bags;clea n container

#3450

Ambient Temp.
Refrigerated
Ambient Temp.
Refrigerated

Criteria for Outbreak Association
Isolation of organism of same subtype (PFGE) from > 2 people.
Isolation of organism of same subtype (PFGE) as stool and/or food isolates.
Detection of enterotoxin in implicated food; isolation of enterotoxin-producing strain of S. aureus; isolation of > 105 organisms/g from implicated food, provided specimen properly handled.
Isolation of organism, same serotype/subtype, from > 2 people.
Isolation of organism from implicated food, same serotype /subtype as stool isolates.
Isolation of toxigenic organism from > 2 people.
Isolation of toxigenic organism from implicated food.

IV- 38

Etiological Agent
Vibrio parahaemolyticus

Incubation Period
4 30 h

Clinical Syndrome Diarrhea

Yersinia enterocolitica

1 10d, usually 4 6d

Diarrhea, abdominal pain (often severe) may mimic appendicitis

Required Collection Submis- How to

Specimen Vial

sion Form Ship

Criteria for Outbreak Association

Stool Food
Stool Food

Para-Pak #0555
Zip-lock bags;clea n container
Para-Pak #0555
Zip-lock bags;clea n container

#3416 #3450
#3416 #3450

Ambient Temp.
Refrigerated

Isolation of Kanagawa-positive organism from > 2 people.
Isolation of > 105 Kanagawa-positive organisms/g from implicated food.

Ambient Temp.
Refrigerated

Isolation of pathogenic strain or serotype from > 2 people.
Isolation of pathogenic strain or serotype from implicated food.

References:

1.

Centers for Disease Control and Prevention. CDC Surveillance Summaries, March 17, 2000. MMWR 2000; 49(No. SS-1).

2.

Bryan, F.L. 1982. Diseases Transmitted by Foods. A Classification and Summary, 2nd ed. Centers for Disease Control, Atlanta.

3.

Bryan, F.L. 1995. Outbreaks of Food-Borne Disease, p. 209-226. In P. Murray et al. (ed.), Manual of Clinical Microbiology, 6th ed. ASM Press,

Washington D.C.

IV- 39

IV- 40

GENITOURINARY SLIDES 404-327-7990
INTRODUCTION
The Bacteriology Unit examines smears of suspected material for the presumptive diagnosis of trichomonads, yeast, Haemophilus ducreyi, or Neisseria gonorrhoeae. This method of diagnosing N. gonorrhoeae is satisfactory for male smears; however, in females and young children, where organisms may be scarce or atypical, microscopic methods are not acceptable
SPECIMEN COLLECTION/LABELING/REQUISITION FORM
Trichomonads/Yeast
Use a cotton tipped applicator to collect vaginal discharge. Roll a thin smear onto a glass slide and air dry.
Haemophilus ducreyi
1. Ulcer Cleanse ulcer thoroughly with saline. Obtain serous material from the border on a swab. Roll swab (in one direction) onto a glass slide. Air dry.
2. Lymph node (bubo) aspirate After local preparation, aspirate material from bubo and prepare a thin smear on a glass slide. Air dry.
Neisseria gonorrhoeae:
Male urethra: Obtain discharge on cotton swab, or if discharge cannot be expressed, use a calcium alginate swab inserted 2-3 cm. into interior urethra, rotating gently as swab is withdrawn. Roll a thin smear onto a slide and air dry.
Note: Use FROSTED END slides and properly label with patient identifier and collection date. A separate slide must be submitted for each direct examination, e.g., trichomonads/yeast, Haemophilus ducreyi, and Neisseria gonorrhoeae.
Requisition Form
Complete lab form #3415 and include the following: 1. Unique patient identifier (name or number). 2. Date of specimen collection. 3. Test requested (trichomonads/yeast, H. ducreyi, or N. gonorrhoeae). 4. Submitter's name and address. 5. Type of specimen collected. 6. Patient's race, sex, age, and address, if available.
IV- 4 1

The patient identifier (name, number, or both) indicated on the requisition form must match that written on the slide. Unlabeled slides will not be tested.
SHIPMENT OF SPECIMENS
1. Place slide securely in the plastic slide holder provided (outfit #0545, available from Laboratory Services and Supply, 404-327-7920).
2. Place the plastic holder and requisition form in the cardboard mailing container with the Decautr address label (orange).
3. Seal the lid of the outside container with tape. 4. Send by first-class mail, common carrier, or courier. 5. It is best to send slides to the laboratory on the day of collection, but if there is any delay
in shipment, hold specimens at ambient temperature.
REPORTING AND INTERPRETATION OF RESULTS
Results of microscopic examinations will be completed the day of receipt, if slides are received by 12:00 p.m.; otherwise, they will be ready the next day. Results will be reported as follows:
1. Trichomonads/yeast (female): a. Trichomonads Present b. Yeast-like Cells Present c. No Trichomonads Seen, No Yeast-like Cells Seen
2. Haemophilus ducreyi: a. Negative Presumptive: No organisms resembling Haemophilus ducreyi seen on direct smear. b. Positive Presumptive: Organisms resembling Haemophilus ducreyi seen on smear.
3. Gonorrhea smears: a. Positive: Gram-negative intracellular diplococci resembling gonococci present. b Suggestive: Extracellular Gram-negative diplococci present suggestive but not typical of gonococci. c. Negative: No Gram-negative intracellular diplococci resembling gonococci seen. If material is scarce, the report will read: Due to scarcity of material negative results may be of no value. Please resubmit. d. Unsatisfactory: See section below on unacceptable specimens.
NOTE: When there are many to numerous pus cells present in the absence of bacteria, the Laboratory will make the following comment to the report: 1. Smears with >10 WBC/field: "Numerous pus cells present - Suggestive of non-
gonococcal urethritis." 2. Smears with 5-9 WBC/field: "Many pus cells present - Suspicious of non- gonococcal
urethritis."
IV- 4 2

UNACCEPTABLE SPECIMENS 1. Smear is too thick/too thin for accurate interpretation. 2. Slides broken in transit. 3. No patient identifier on specimen. 4. Patient identifier on specimen does not exactly match that on form. 5. Smear is fixed for a PAP smear examination.
IV- 4 3

IV- 4 4

GROUP A STREPTOCOCCUS 404-327-7990
INTRODUCTION
The Bacteriology Unit accepts specimens from public health care providers for the detection of Group A Streptococcus and other beta-hemolytic streptococci. Reference cultures will be accepted from public and private health care providers for identification and/or serogrouping of beta-hemolytic streptococci. Culture is the method used for isolation of the organism, and latex agglutination is used for serogrouping isolates. In cases of systemic infections or necrotizing fascitis, or if acute rheumatic fever or glomerulonephritis are suspected, referred cultures of Group A Streptococcus will be forwarded to CDC for molecular typing. (See Special Bacteriology Section).
SPECIMEN COLLECTION/LABELING/REQUISITION FORM
Throat, nasal, skin, and wounds are suitable specimens for the isolation of Group A Streptococcus. The sterile swab supplied in outfit #0560 should be used for throats, skin, and wound swabs. Outfits are available from Laboratory Services and Supply, 404-327-7920. For nasal swabs, a sterile cotton-tip flexible wire, available commercially, is recommended.
1. Throat: After adequately exposing and illuminating the pharynx, rub tonsils and pharynx with the swab provided. Be careful to obtain any exudate present and avoid the tongue and uvula tissues.
2. Skin: Remove the crusts of the pustule or vesicle cap and rub swab firmly into the lesion. 3. Wound: Follow the same procedure as described for skin. If the area is dry, moisten the
swab first. 4. Nasal: Moisten the flexible wire swab and introduce it gently along the floor of the nasal
cavity, under the middle turbinate, until the pharyngeal wall is reached.
Place swab in the silica gel envelope, according to instructions supplied with the outfit. Place the silica gel package in the polyfoil kraft envelope, and clearly write the patient's name or other unique identifier in the space provided.
Use requisition form #3418 and supply the following information: (1) Patient identifier (name or number). (2) Date of specimen collection. (3) Name and telephone number of clinician to contact. (4) Submitter's name and address. (5) Patient's race, sex, age, and address, if available.
The patient identifier on the form should match that on the specimen. Unlabeled specimens will not be tested.
The Group A Streptococcus outfit may be used for the isolation of any beta-hemolytic Streptococcus from throat, nasal, skin, or wound infections. Specimen of "throat swab" and
IV- 4 5

examine for "Group A Streptococcus" will already be indicated on form #3418, which is supplied in the outfits. If a different type of specimen is submitted, or if an organism besides Group A Streptococcus is suspected, this information MUST be indicated on the requisition form. SHIPMENT OF SPECIMENS Place the polyfoil envelope and requisition form in the brown mailing envelope provided. Specimens may be sent to the Laboratory by first-class mail, common carrier, or courier. If there is any delay in shipment, hold specimens at room temperature. REPORTING AND INTERPRETATION OF RESULTS Culture results of beta-hemolytic Streptococcus will be completed 18-24 hours after receipt of the specimen. Any Group A Streptococcus detected will be reported. Other groups of betahemolytic Streptococci will be reported if they are the predominate organism present. The report will read "No Group A Streptococcus Found by Culture" for negatives; if no growth is detected this also will be noted. For positives, the report will read, "Group A Streptococcus Found by Culture," or Group B, C, F, G Streptococcus Found by Culture, Predominate Organism Present." Reports of positive specimens will be telephoned to submitters the day testing is completed. UNACCEPTABLE SPECIMENS 1. Specimens not submitted in the silica gel outfit (or other suitable transport outfit
approved by the Bacteriology Unit). 2. Silica gel envelope not sealed.* 3. Specimens received >4 weeks after collection.* 4. No patient identifier on specimen. *Specimens will be tested, but a disclaimer will be added to the report indicating that negative results are questionable.
IV- 4 6

SPECIAL BACTERIOLOGY 404-327-7990
INTRODUCTION
The Bacteriology Unit accepts reference cultures from public and private health care providers for the identification, confirmation, and/or serotyping of bacterial isolates. This includes a wide variety of aerobic, anaerobic, and facultative organisms from clinical sources. Isolates should be submitted as pure cultures. Techniques used in the identification process include a combination of some or all of the following: cellular and colonial morphology, conventional biochemical tests, gas-liquid chromatography (GLC) for metabolic end-product determination, GLC for cell wall fatty acid analysis, and DNA probes. All isolates of Neisseria meningitides, Haemophilus influenzae, Group A Streptococci, Group B Streptococci, Listeria monocytogenes, and Streptococcus pneumoniae recovered from sterile sources should be forwarded to the Bacteriology Unit, either directly or through the Emerging Infections Program (EIP) site. The following services are provided by the GPHL in conjunction with epidemiological investigations and surveillance, and are offered at no charge: N. meningitidis grouping, H. influenzae typing, and Pulsed-field gel electrophoresis (PFGE) for L. monocytogenes. Group A Streptococci, Group B Streptococci, and S. pneumoniae isolates from sterile sources will be forwarded to the Centers for Disease Control and Prevention (CDC) for typing and/or molecular characterization. With the exception of Neisseria gonorrhoeae, antimicrobial susceptibilities are not performed except as an aid to identification. Such requests can be forwarded to the CDC through the Bacteriology Unit by special arrangement. Any unidentified organisms isolated from sterile sources will also be sent to the CDC for further studies, upon request.
Clinical material for the primary isolation of bacteria may also be submitted, although specimens other than feces and throats are usually handled at local laboratories. The organism(s) recovered are then sent for identification as noted above for reference cultures.
The Bacteriology Unit will accept specimens or cultures from environmental sources under the following conditions: (1) when these are associated with human illness; (2) for infection control purposes; (3) during an epidemiological investigation; or (4) by special arrangement. Specimens or cultures from animals will be accepted by special arrangement only.
SPECIMEN COLLECTION/LABELING/REQUISITION FORM
A. Specimens and Cultures for Anaerobic Isolation and Identification:
Aspirates collected with a sterile syringe or tissue specimens are recommended for anaerobic culture. Acceptable clinical specimens include: aspirated pus, transtracheal and lung aspirates, body fluids, tissue (biopsy, surgical, and autopsy), suprapubic aspirate of bladder urine, and sulfur granules from suspected cases of actinomycosis. Pure culture isolates from these sources may be submitted and are preferred over specimens.
IV- 4 7

Unacceptable specimens include: throat, nasopharyngeal, and gingival swabs, sputum, bronchial washings (except those obtained via a protected double lumen catheter or properly done bronchoalveolar lavage), gastric and small bowel contents, feces (except for foodborne illnesses and infant botulism), voided or catheterized urine, and rectal, skin, vaginal, and cervical swabs. Referred cultures from these sources will be accepted only if accompanied by information establishing clinical significance.
Collect specimens with care to avoid contamination with indigenous flora and place under anaerobic conditions immediately. Clearly label both specimens and/or referred cultures with the patient's name or other unique identifier.
B. Specimens and Cultures for Aerobic Isolation & Identification:
Collect all specimens, such as autopsy material, tissues, urine, respiratory and urogenital tract secretions, wounds, abscesses, spinal fluid, and blood, aseptically using techniques appropriate for the particular type of specimen. The Bacteriology Laboratory may be contacted for further information on specific collection methods, if needed. Clearly label both specimens and/or referred cultures with the patient's name or other unique identifier.
See Table 1 for aerobic and anaerobic organisms requiring special handling. In all of the cases noted in Table 1, notify the Bacteriology Unit prior to shipping.
Requisition Form
Complete form #3415 when submitting specimens for aerobic or anaerobic isolation and identification. Use form #3410 when sending referred cultures for aerobic or anaerobic identification, confirmation, and/or serotyping. Include the following information:
1. Unique patient identifier (name or number). 2. Agent suspected or test requested. 3. Submitter's name and address. 4. Name and telephone number of contact person. 5. Date of specimen collection. 6. Source of specimen. 7. Date of transplant (if applicable). 8. Brief clinical history. 9. Patient's race, sex, age, and occupation, if available.
The patient identifier (name or number) indicated on the requisition form should match that written on the specimen or culture. Unlabeled specimens or cultures will not be tested.
IV- 4 8

SHIPMENT OF SPECIMENS AND REFERRED CULTURES (See pages II-1 II-4 of this manual for recent changes in federal shipping guidelines).
Because of problems of maintaining viability and possible overgrowth of normal flora during transit, the mailing of clinical specimens for primary isolation is discouraged. Exceptions include stools for enteric pathogens, throats for Group A Streptococcus, nasopharyngeal swabs for Bordetella pertussis, slides for Neisseria gonorrhoeae and Haemophilus ducreyi, and other specimens in certain unusual circumstances. If specimens for anaerobic isolation are submitted, they should be sent in an anaerobic environmental system available commercially.
Submit referred cultures as pure cultures in the appropriate medium. For anaerobic identification, chopped meat broth, thioglycollate broth, motility test medium (inoculate near the bottom of the tube), or anaerobic blood culture bottles are suitable choices. For aerobic identification, slants of solid medium appropriate for growth of the organism in question are recommended. Use screw-capped tubes and tighten securely. Place a strip of parafilm around the cap of the tube to help prevent loosening of the cap in transit. In all cases, submit young, actively growing subcultures to ensure viability. Various types of agar slants and chopped meat broth are available in limited supply from the Bacteriology Unit.
Wrap the sides and bottom of culture tubes in kyfax packing material or paper towels to prevent breakage. Use outfit #0505, "Culture Referral Isolation for Identification," available from Laboratory Services and Supply, 404-327-7920, and follow these instructions: 1. Place culture wrapped in packing material in the biohazard bag provided. 2. Put the requisition form in the pouch in the front of the bag. 3. Place the biohazard bag in the orange-labeled cardboard mailing container (Decatur
address) and secure the lid with tape. 4. Place the return address on the outside of the container. 5. Send by first class mail, common carrier, or courier. 6. Avoid submitting cultures in petri dishes, but if necessary, cushion them with absorbent
material and securely package in leak-proof containers. Seal culture plates for anaerobic identification in an anaerobic "bag" system before packaging.
See Table 1 for instructions on shipment of organisms requiring special handling.
REPORTING AND INTERPRETATION OF RESULTS
Organisms are identified to the genus and species level when there is agreement with all appropriate data, such as cultural, morphologic, biochemical, gas-liquid chromatography, and cell wall fatty acid analysis. Occasionally an organism can be identified accurately only to the genus level. Genus and species designations are consistent with designations in the Manual of Clinical Microbiology and are updated according to publications in the International Journal of Systematic Bacteriology. The identification of the organism only will be reported; results of specific tests, such as biochemical reactions, must be requested on the requisition form when the culture is submitted. When serotyping is requested and available, the appropriate serotype or serogroup will be reported. Unidentified organisms isolated from sterile sources may be
IV- 4 9

forwarded to CDC, but those isolated from nonsterile sites must be accompanied by a detailed clinical history to justify sending to CDC. Culture results for the identification of aerobic, facultative, and anaerobic bacteria are usually completed within seven working days, but may require up to fifteen working days, depending upon the organism. Mixed cultures, fastidious, slow-growing, or nutritionally-deficient bacteria may occasionally require additional time beyond the fifteen working days for a complete identification. Results of serotyping are usually completed as follows: Neisseria meningitidis (13 working days); Haemophilus influenzae (2-3 working days); and beta hemolytic Streptococcus (3-4 working days). Cultures referred to the CDC may require up to six months for a final identification. If results are urgent, this should be specified on the requisition form and a preliminary and/or final report will be telephoned to the submitter. If the identification is inconsistent with the organism suspected, the submitter will also be notified by telephone. UNACCEPTABLE SPECIMENS 1. Cultures broken in transit. 2. Non-viable cultures: all cultures received will be subcultured upon receipt. Every
attempt will be made to obtain viable growth. If no growth occurs, the submitter will be notified by telephone and a report will be issued immediately. Another subculture will be requested, if available. 3. Cultures grossly overgrown with contaminants. 4. No patient identifier on the specimen or culture. 5. Specimens improperly collected or submitted (see section on specimen collection and shipment).
IV- 5 0

Organism Bacillus anthracis
Brucella species
Clostridium botulinum
Clostridium perfringens
Corynebacterium diphtheriae
Francisella tularensis

Table 1. Organisms Requiring Special Handling
Special Instructions and Requirements
Aspectically collect specimens from lesion, contaminated hair products, or sputum. Send specimens refrigerated in sterile containers (container not provided). Subculture isolates to blood or nutrient agar slants. Send suspected isolates in culture referral outfit (#0505) at ambient temperature. USE BIOLOGICAL SAFETY HOOD. Do not create aerosols.
Aseptically collect multiple blood samples, infected tissues, abscess material, bone marrow, or liver biopsies. Refrigerate clinical specimen if delay in inoculation of primary plating medium or delay in shipment is anticipated. Send specimens refrigerated in sterile containers (container not provided). Subculture isolates to blood, chocolate, or nutrient agar slants. Send suspected isolates in culture referral outfit (#0505) at ambient temperature. USE BIOLOGICAL SAFETY HOOD.
See section on Foodborne Illness for further details on food intoxication and infant botulism. For wound infections, submit material from wound, refrigerated with cold pack, in an anaerobic environment system. Send suspected isolate in chopped meat broth or motility test medium (inoculate near bottom of tube) in culture referral outfit (#0505) at ambient temperature. Specimens and isolates will be forwarded to CDC for isolation, confirmation, and/or toxin testing.
See Foodborne Outbreaks Section for further details on food intoxication. Submit material from site of infection, refrigerated with cold pack, in an anaerobic environment system; or send suspected isolate in chopped meat broth or motility test medium (inoculate near bottom of tube) in culture referral outfit (#0505) at ambient temperature.
Collect throat or skin lesion swabs (use Strep outfit #0560 or place on Loeffler's agar slant). Subculture suspected isolates to Loeffler or cystine blood agar slants. Toxigenicity testing will be performed at CDC. Send suspected isolates in culture referral outfit (#0505).
Aseptically collect material from lesions, lymph nodes, gastric and nasopharyngeal washings, sputum, pleural fluid, and bronchial secretions (pulmonary tularemia), and conjunctival scrapings (ocularglandular tularemia). Ship specimens in sterile containers (not provided) on dry ice. Subculture isolates to chocolate agar slants with IsoVitaleX. Send suspected isolates in culture referral outfits (#0505) at ambient temperature. USE BIOLOGICAL SAFETY HOOD AND EXTREME CAUTION. Send by courier or receipted mail.
IV- 5 1

Table 1. (Continued) Organisms Requiring Special Handling

Organism

Special Instructions and Requirements

Haemophilus ducreyi

Collect specimens from lesions or inguinal bubo. Inoculate onto enriched chocolate agar with vancomycin. Incubate 33-35o C in 5-10%
CO2 in water-saturated atmosphere. Except for slides, referred cultures only will be accepted. (See separate section for submission of
genitourinary slides).

Haemophilus influenzae

For serotyping and/or culture confirmation, submit 18-24 hr. subculture on chocolate slant (slants may be obtained from the GPHL). Submit through the EIP site, by mail, or by courier.

Leptospira

Collect blood or spinal fluid during first 10 days of illness, and urine (3 consecutive samples) from second to fourth week of illness. Obtain Ellinghausen medium and instructions for inoculation from the Bacteriology Unit prior to specimen collection. Immediately inoculate tubes and submit at room temperature to the Bacteriology Unit. Inoculated cultures will be read for up to six weeks before reporting as negative. Positive cultures will be reported as soon as detected and confirmed.

Neisseria gonorrhoeae

For culture confirmation, submit 18-24 hr. subculture on chocolate slant or emulsify fresh growth in trypticase soy broth with 20% glycerol and freeze. Submit preferably by overnight mail (slant) or frozen on dry ice (broth). See separate section for GC culture screening.

Neisseria meningitidis

For serogrouping and/or culture confirmation, submit 18-24 hr. subculture on chocolate slant (slants can be obtained from the GPHL). Submit through the EIP site, by overnight mail, or by courier.

Pertussis

See separate section on Bordetella pertussis

Pseudomonas mallei & P. pseudomallei

Aseptically collect blood, sputum, or pus. Send refrigerated in sterile containers (not provided). Subculture isolates to nutrient or infusion agar slant. Send suspected isolates in culture referral outfits (#0505) at ambient temperature. Send by courier or receipted mail.

Staphylococcus aureus

Submit coagulase positive isolates from outbreaks or multiple isolates from different sources in same patient. Submit on nutrient or heart infusion agar slants. Documentation must accompany specimens. Isolates will be typed by pulsed-field gel electrophoresis.

IV- 5 2

Organism
Yersinia pestis

Table 1. (Continued) Organisms Requiring Special Handling
Special Instructions and Requirements
Aspirate fluids from lymph nodes (bubonic plague); collect sputum or tracheal aspirates (pneumonic plague); collect blood samples for culture bottles. Submit specimens in sterile containers (not provided), refrigerated with ice packs. Subculture isolates to blood or infusion agar slants. Send suspected isolates in culture referral outfit (#0505) at ambient temperature. USE BIOLOGICAL SAFETY HOOD AND EXTREME CAUTION. Do not create aerosols. Send by courier or receipted mail.

IV- 5 3

IV- 5 4

Microbial Immunology Unit
Unit Personnel
Manager - Sandra Watkins, M.S.A. Program Assistant - Selina Price Associate - Kim Kilgour, B.S.
IV- 5 5

IV- 5 6

MICROBIAL IMMUNOLOGY UNIT INFECTIOUS DISEASE SEROLOGY
404-327-7970
INTRODUCTION
The Microbial Immunology Unit performs many infectious disease serology. Serology for HIV (Human Immunodeficiency Virus), is performed in the Virology Unit. Various serologic procedures are performed for a variety of bacterial, parasitic, and viral agents. Hepatitis B serology is performed for county health departments, and Georgia Department of Human Resources (GDHR) agencies, only. Tests not performed in the Public Health Laboratory are forwarded to CDC, if they provide the requested testing.
SPECIMEN COLLECTION/LABELING/REQUISITION FORM
Collection: Using Universal Precautions, and standard venipuncture technique, collect approximately six milliliters of whole blood (for serum) in a red top tube (no additive), labeled with patient's identifier (name, first and last, or number), date, and name of the submitter. Use a marker that will not fade, smear, or run during transportation. Use proper size needle (large enough to prevent hemolysis of the red blood cells) for the vein location and age of the patient. Allow blood specimen to clot, at least 30 minutes undisturbed, at room temperature, and transport, or place in the refrigerator for transporting. Collect blood specimens in, or transfer them to non-breakable, leak resistant tubes. Specimens should be transported as soon as possible, do not hold over 7 days. Specimens over 14 days old are unacceptable. Many of the procedures we perform are not approved for use with plasma. Therefore, please submit only serum or whole blood without anticoagulants, not plasma.
Collect cerebrospinal fluids (CSF) according to proper hospital procedure. CSF contaminated with blood or grossly contaminated with bacteria is unacceptable.
Labeling: All specimens must be labeled with patient identification (name or number), in acceptable testing condition, and accompanied by a completed requisition form. If the form is not specific for one test or a set of tests, the specific testing requested must be hand-written in the proper area, e.g., "viral serology" is not acceptable, the specific agent, e.g., "CMV", must be clearly requested. Failure to provide proper patient information may result in testing delays.
Requisition Form: Use Form #3432 for all tests performed by the Microbial Immunology Unit. There is a single requisition form for all serological tests performed, including the RPR and EIA tests for syphilis, Premarital serology (including rubella on females), Hepatitis B (GDHR facilities and county health departments only), and Other Serology. Completely fill out the form and include the following information:
1. Unique patient identifier (name or number). 2. TEST(S) REQUESTED (Please check only the corresponding box for test(s)
requested).
IV- 5 7

3. Date specimen collected. 4. Submitter's name, address, and code number, where applicable. 5. For hepatitis the reason for testing, e.g., routine, or prenatal. 6. Any information the submitter needs for patient identification, e.g., chart number,
address. 7. The date of onset of illness, if applicable. 8. Race, sex, and age, where applicable, e.g., hepatitis testing.
SHIPMENT OF SPECIMENS
Use outfit #0500, available from Laboratory Services and Supply, 404-327-7920, and follow the specific instructions below. Specimens may be mailed or delivered to the laboratory by courier.
Shipping Instructions for USPS. and Couriers: Place the tubes of blood in protective, leak resistant, double-walled containers, e.g., aluminum and cardboard box, for transport. Wrap the requisition form around the inner (aluminum) can, secure with a rubber band and place in the outer container. If a screw-cap outer container is used, the screw-cap must be secured with tape or the Postal Service will return it for taping. Up to 50 milliliters of blood may be transported in one package (U.S. postal regulations). Therefore, an individual tube of blood may be placed in the metal can, with the requisition form secured to the outside by a rubber band, and several aluminum cans placed in one cardboard box for transporting.
Shipping Instructions for Courier Services Only: Tubes of blood may be placed in leak proof biohazard bags. Wrap brown absorbent material around the tube, then secure with a rubber band. Place the requisition form in the sleeve located on the outside of the bag.
REPORTING AND INTERPRETATION OF RESULTS
Table 1 (pages IV-61 through IV-63) summarizes the interpretation of results for all serological tests performed in the Microbial Immunology Unit. Table 2 (page IV-64) gives the turnaround times for all of the same serological tests. Turn-around-time after the receipt of the specimen depends on the testing methodology and the frequency of testing. The frequency of testing depends on the demand for a specific test. Several tests are performed daily, while others are performed weekly. The turnaround time for specimens referred to CDC depends on CDC's schedule, which varies from laboratory to laboratory.
UNACCEPTABLE SPECIMENS
1. Spinal fluid obviously contaminated with bacteria or blood; 2. All specimens:
a) Not approved for testing by the indicated method, e.g., plasma for RPR. b) Grossly hemolyzed, lipemic, turbid, or contaminated. c) Over 14 days old.
IV- 5 8

d) Broken in transit. e) Insufficient quantity for testing. f) No identification on specimen. g) Name on tube and form does not match. The submitter will be notified of all rejected specimens. Most serologic services are available to both the public and private sectors. However, hepatitis B testing is limited to the public health care providers, and not available to the private providers.
IV- 5 9

IV- 6 0

Table 1. Testing Results

Agent
California EncephaLitis
Cytomegalovirus (CMV)

I g G1 IgM1
IgG IgM

Method IFA1
EIA1

Eastern

IgG

IFA

Equine

IgM

Encephalitis

VCA1 IgG

Epstein-

VCA

EIA

Barr Virus

IgM

(EBV)

EBNA 1

IgG

HBs 1

Hepatitis B

Hbe1

Virus (HBV)6

EIA AntiHBs 1

AntiHBc1

Herpes Simplex Virus (HSV)

Type 1

EIA

Type 2

Lyphogranuloma

IFA

Venereum (LGV)

Test Result Interpretation1

Negative

Positive2

Diagnostic

IgG <1:16 IgM <1:16

IgG >1:16 Four-fold rise in titer IgM > 1:16 between paired sera4

No IgG Detected No IgM Detected
IgG <1:16 IgM <1:16

IgG Detected IgM Detected
IgG >1:16 IgM > 1:16

IgM detected and/or significant rise in titer between paired sera 4,5
Four-fold rise in titer between paired sera4

Presumptive3 > 1:16
IgM Equivocal
> 1:16

No IgM Detected
No IgM Detected
No IgG Detected
Negative
Negative
Negative

IgG Detected
IgM Detected
IgG Detected
Positive
Positive
Positive

Current Infection: Positive VCA IgG and IgM, and EBNA IgG Negative

Positive VCA IgM Only

Recurrent Infection: Positive VCA IgG, IgM and EBNA IgG
Positive HBs

None

Negative

Positive

No IgG Detected

IgG Detected

Significant difference between paired sera4,5

None

<1:10

> 1:10

Four-fold rise in titer between paired sera4

> 1:10

IV- 6 1

Agent Mumps

Murine typhus

Mycoplasma Pneumonia

Parvo-

IgG

Virus

IgM

Q-Fever

Method EIA IFA EIA EIA
IFA

Rocky Mountain

IFA

Spotted Fever (RMSF)

Rubeola

IgG

(Measles

EIA

IgM

Rubella (German Measles)
St. Louis Encephalitis
Syphilis

IgG

IgM

EIA

Premarital

IgG

IFA

IgM

RPR1

Agg1.

Confir-

matory

EIA

EIA

FTA

IFA

Test Result Interpretation1

Negative

Positive2

Diagnostic

No IgG Detected

IgG Detected

Significant difference between paired sera4,5

<1:16

> 1:16

Four-fold rise in titer between paired sera4

No IgG Detected
No IgG Detected;
No IgM Detected
Phase I <1:16 Phase II <1:16

IgG Detected
IgG Detected
IgM Detected
Phase I >1:16 Phase II >1:16

Significant difference between paired sera4,5
IgM detected and/or significant increase between paired sera4,5
Four-fold rise in titer between paired sera4

< 1:16

> 1:16

Four-fold rise in titer between paired sera4

No IgG Detected
No IgM Detected

IgG Detected
IgM Detected

IgM detected and/or
significant increase
between paired sera 4,5

No IgG Detected
No IgM Detected

IgG Detected
IgM Detected

IgM detected and/or
significant increase
between paired sera 4,5

NonImmune

Immune

Not Applicable

IgG <1:16 IgM <1:16

IgG >1:16 Four-fold rise in titer IgM > 1:16 between paired sera4

NonReactive
NonReactive

Reactive > 1:1
Reactive

RPR and EIA Reactive

NonReactive

Reactive

RPR, EIA, FTA

Presumptive3 None
> 1:128 None None
Phase I > 1:128 PhaseII > 1:128
> 1:128
IgM Equivocal
Not Applicable
Not Applicable > 1:16
Reactive RPR and Equivocal EIA
Equivocal EIA

IV- 6 2

Agent Syphilis
Toxoplasmosis
Varicella Zoster West Nile Virus

VDRL (CSF1) IgG
IgM
IgG IgM

Method Agg1 EIA
EIA EIA

Western

IgG

IFA

Equine

IgM

Encephalitis

Test Result Interpretation1

Negative

Positive2

Nonreactive Reactive

Diagnostic VDRL Reactive

No IgG Detected
No IgM Detected
No IgG Detected
No IgG Detected No IgM Detected
IgG <1:16 IgM <1:16

IgG Detected
IgM Detected
IgG Detected
IgG Detected IgM Detected
IgG >1:16 IgM > 1:16

IgM detected and/or significant increase between paired sera 4,5
Significant increase between paired sera4,5
IgM detected and/or significant increase between paired sera4,5
Four-fold rise in titer between paired sera4

Presumptive3 Reactive VDRL IgM Equivocal
None
IgM Equivocal
> 1:16

Abbreviations (in alphabetical order)1

Agg. CSF EBV VCA EBV EBNA EIA FTA HBs HBe

Agglutination Cerebrospinal Fluid Epstein-Barr Virus capsid antigen Epstein-Barr nuclear antigen Enzyme Immunoassay Fluorescent treponemal antibody Hepatitis B surface antigen Hepatitis B E antigen

Anti-HBs Anti-HBc IFA IgG IgM RPR VDRL

Hepatitis B surface antibody Hepatitis B core antibody Indirect Fluorescent Antibody Immunoglobulin G Immunoglobulin M Rapid Plasma Reagin Veneral Disease Research Laboratory

2A positive result indicates natural or acquired immunity, especially for vaccine-preventable diseases

3Presumptive results identify a significant result for a single (not paired) serum, and need confirmation by clinical symptoms, recollection of specimen for retesting, or if applicable, submission of a convalescent specimen.

4Paired sera (acute and convalescent) dates of collection and date of onset of illness are needed for proper interpretation of results.
5A significant difference is determined by instructions given in individual enzymeimmunoassay procedures, and may differ between manufacturers.

6Performed for county health departments and DHR facilities only.

FOR ADDITIONAL INFORMATION REGARDING TEST INTERPRETATION CALL THE MICROBIAL IMMUNOLOGY LABORATORY AT (404) 327-7970

IV- 6 3

Table 2. Turnaround Times

Agent

California Encephalitis IgG2/IgM2

Cytomegalovirus IgG/ IgM

Eastern Equine Encephalitis IgG/ IgM

Epstein-Barr virus VCA2IgG/IgM EBNA2IgG

Hepatitis A

Hepatitis B Diagnosis

Surface antigen

Total antibody

core antibody

e-antigen (performed on surface antigen-

positive specimens only)

Herpes simplex 1&2

Lymphogranuloma Venereum

Mumps

Murine typhus

Mycoplasma

Parvovirus IgG/IgM

Q Fever IgG

Rocky MountainSpotted Fever

Rubella Immune Status (EIA)2

IgG/ IgM

Rubeola IgG/IgM

St. Louis Encephalitis IgG/ IgM

Syphilis RPR2Non-Reactive

RPR Reactive

.

Confirmatory Non-Reactive

Confirmatory Reactive FTA2 Non-Reactive

FTA Reactive

Toxoplasmosis IgG /IgM

West Nile Virus IgG/ IgM

Western Equine Encephalitis IgG/ IgM

Varicella zoster VDRL2 (CSF2 only)

Turnaround Time (Working Days)1 10-12 days 5-7 days 10-12 days
5-7 days 5-7 days 10-12 days
3 days 3 days 3 days 7 days
5-7 days 10-12 days 5-7 days 5-7 days 5-7 days 7-10 days 5-7 days 5-7 days
1-3 days 5-7 days 5-7 days 10-12 days
1-2 days 2-3 days 2-3 days 2-3 days 5-7 days 5-7 days 5-7 days 10-12 days 10-12 days 5-7 days 5-7 days

1Special arrangements may be made in the case of an emergency. 2Abbreviations: IgG, Immunoglobulin; G; IgM, Immunoglobulin M; VCA, Epstein-Barr viral capsid antigen; EBNA, Epstein-Barr nuclear antigen; EIA, Enzyme Immunoassay; RPR, Rapid Plasma Reagin; FTA, Fluorescent treponemal antibody; VDRL, Veneral Disease Research Laboratory; CSF, Cerebrospinal Fluid.
IV- 6 4

Mycobacteriology/Mycology Unit
Unit Personnel
Associate - Jane Bush, B.S. Manager - Elizabeth Dennis, M.S.
IV- 6 5

IV- 6 6

ISOLATION AND IDENTIFICATION OF MYCOBACTERIA 404-327-7940
INTRODUCTION
The Mycobacteriology section accepts specimens for isolation and identification of Mycobacterium tuberculosis and other mycobacteria which may cause disease under certain circumstances. The services of this laboratory are available to both public and private health care providers.
SPECIMEN COLLECTION/LABELING/REQUISITION FORM
Although the most common specimen received is expectorated sputum, the GPHL accepts specimens of various other types: sputum collected by aerosol induction, laryngeal swab, or gastric lavage, urine (voided early morning, catheterized from bladder, or cystoscopic from kidney), pus (aspirated or on swab), tissue (biopsied lymph node or biopsied portions of organs, usually lung), and body fluids (cerebrospinal, pleural, pericardial, or joint).
If a case has not been diagnosed as tuberculosis, a series of three to six single, early morning sputum specimens should be collected on successive days and transported to the laboratory as soon as possible. Specimen collection outfits are available at no charge from the Laboratory Supply Office. Each outfit consists of a rigid mailing container that holds a specimen tube (50 mL plastic screw-cap) and a plastic bag with two pouches. All caps and the zip-lock pouch should be closed tightly to prevent leakage. Collection instructions are enclosed with each shipment of mailing containers, and the information provided there should be communicated to the patients to help ensure that the Mycobacteriology Unit receives adequate specimens. Even the highest quality laboratory work can not produce good results on a poor specimen.
The plastic centrifuge tube must be labeled with the patient=s name. Tuberculosis Form 3412 should be filled out completely, giving the following information: patient=s name (be sure it is legible and evident which is the first and which is the last name), address including county of residence, race, sex, date of birth, type of specimen, date collected, and name and address of submitter. All information requested on the form should be provided on all request forms, since the laboratory information system creates a unique medical record for each patient based on these demographics. There is a nominal charge of $8.00 per specimen for private health care providers. Fee stamps are available from the laboratory administrative office and should be attached to the requisition form as payment for each specimen.
SHIPMENT OF SPECIMENS
The specimen should be collected in the plastic centrifuge tube and the cap tightened securely. The tube must be labeled legibly with the patient=s name. The specimen is placed in the zip-lock portion of the plastic bag and a Tuberculosis Form 3412, marked for "Routine for clinical specimen," in the front pouch. The bag is placed in the mailing container and the lid screwed on tightly. The screw-cap of the outer mailing container should be secured with tape to meet Postal
IV- 6 7

Service requirements. The specimen should be mailed or delivered to the laboratory as soon as possible after collection to avoid overgrowth of bacteria other than M. tuberculosis. If mailing is delayed overnight, the specimen should be refrigerated.
Shipment of Specimens for Identification (See pages II-1 II-4 of this manual for recent changes in federal shipping guidelines.)
Cultures for identification and/or drug susceptibility testing should be submitted on solid media after good growth appears. A Tuberculosis Form 3412, appropriately marked for either "Culture for identification" or "Culture for susceptibility tests," should be filled out completely and legibly and submitted with each isolate. If an isolate submitted for identification is M. tuberculosis, susceptibilities will be performed. Glass tubes must be wrapped with cushioning material before being placed into the zip-lock pouch of the plastic bag. Seal the pouch securely. The Form 3412 should be placed in the front pouch of the bag, which is then placed inside the outer shipping container. All caps should be tightened securely.
MGIT tubes showing growth of acid-fast bacilli may be submitted for identification and drug susceptibility testing. A MGIT tube must be sent in accordance with postal/shipping regulations governing infectious substances. They may be centrifuged and the supernatant decanted, leaving the organisms retained in the sediment pellet in the original tube, which should then be placed inside one of the 50 mL centrifuge tubes, capped, and packaged as instructed for specimens. Uncentrifuged MGIT tubes containing broth must be placed inside a 50 mL centrifuge tube, capped securely, and packaged as instructed for specimens. In case of breakage of the MGIT tube, the broth will still be contained inside the 50 mL conical tube, provided all caps have been securely tightened.
REPORTING AND INTERPRETATION OF RESULTS
Results for all mycobacterial testing are reported to the submitter as soon as they are available. In addition copies of reports for positive specimens (i.e. positive AFB smears, positive TB identification, and susceptibilities) are sent to TB Control. If the submitter is a private health care provider, copies of positive reports are sent to the health department in the county of residence of the patient, if such information was supplied on the submission form. No results can be provided to a private health care provider unless the specimen was submitted by the provider.
Microscopic Examination Mycobacteria contain unique mycolic acids and lipids in their cell walls. Primary stains bind tightly to these compounds and are not removed by exposure to strong mineral acids or acidalcohol; therefore, mycobacteria are called Aacid-fast bacilli@ (AFB). Fluorochrome stained slides are prepared from all specimens the day they are received in the laboratory, and results are reported within 24 hours. The slides are examined using a fluorescent microscope for the
IV- 6 8

presence of bacilli showing a yellow-green fluorescence. Results are reported as "no AFB found"; "+/-" (1-3 AFB/slide); "1+" (4-36 AFB/100 fields); "2+" (4-36 AFB/10 fields); "3+" (436 AFB/field); or "4+" (>36 AFB/field). Submitters are notified by telephone of a positive smear on a new patient.
Culture A tube of solid medium (Lowenstein-Jensen agar) and a tube of liquid medium (Bactec MGIT broth) are inoculated from each specimen. These cultures are incubated for six weeks before a report of ANo Growth@ is issued. If growth in either medium occurs at any time during the six weeks, identification procedures begin. Use of the new Bactec MGIT system facilitates more rapid detection of mycobacterial growth and has decreased turn around time on specimens from patients who are not on antituberculosis drugs by two to three days. As mycobacteria grow in the MGIT broth tubes, they deplete the oxygen and a substrate in the tube begins to fluoresce. The Bactec 960 instrument reads the tubes every hour and signals a positive reaction when it detects fluorescence.
Identification As soon as growth has been detected, a culture is stained for acid-fast organisms. Sometimes the growth is made up of other bacteria which are not acid-fast, and the specimen is reported as AContaminated.@ Cultures showing acid-fast organisms are subjected to nucleic acid probe testing. Four gene probe tests are available and confirm the identification of M. tuberculosis complex, M. avium complex, M. gordonae, and M. kansasii; an appropriate report based on the gene probe identification is issued immediately. If the organism does not react with the gene probes, it is subcultured to solid medium and, after growth has been obtained, identification is performed utilizing HPLC (High Performance Liquid Chromatography) and/or special biochemical studies. The special biochemical studies usually require four to eight weeks for identification of the organism, whereas HPLC provides rapid identification.
Organisms which test positive with the M. tuberculosis complex gene probe are reported as AM. tuberculosis complex@. This complex consists of the following species: M. tuberculosis, M. bovis, M. bovis BCG, M. africanum and M. microti. Gene probe testing cannot distinguish between these organisms because they contain closely related nucleic ac